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ABSTRACT 
 
 
 Glaucoma refers to a group of conditions characterized by death of RGCs, 
increase in intraocular pressure is usually a precursor to glaucoma and irreversible optic 
neuropathy leads to visual impairment and blindness. Recent advances have seen a surge 
of new ideas and technologies to aid in the early detection, efficacious treatments and 
neuroprotection. Despite advances we face several challenges in understanding the 
pathophysiology of glaucoma. One of the many challenges scientists and 
ophthalmologists are facing is, to better understand IOP, its role in glaucomatous damage 
and design safer, more predictable IOP-lowering therapies. Another challenge is to find a 
practical method or develop tools to understand the molecular pathways to study RGC 
function and health to develop novel therapies for vision loss. This work leads to three 
complementary insights on how to address these challenges. First, we used a novel 
systems genetics approach to identify and validate genetic modifiers of IOP using the 
enlarged BXD family of strains in combination with human GWAS glaucoma cohorts. 
This will pave the way for improved drug development tailored to individual genotypes 
for POAG. Second, we have combined systems genetics, bidirectional studies using 
multiple species, meta-analyses, immunohistochemistry, FACS sorting and gene 
knockdown studies to identify and validate the identity of a genetic modulator of Sncg, a 
gene that has been previously implicated in RGC death in glaucoma. Outcomes of the 
investigation may provide clues to understanding the molecular mechanisms that account 
for the degenerative changes in RGCs in glaucoma. Third, we optimized a feasible, 
reproducible, standardized flow cytometry-based protocol for the isolation and 
enrichment of homogeneous RGC. This will allow for future careful assessment of 
important cell specific pathways in RGC to provide mechanistic insights into the 
declining of visual acuity in aged populations and those suffering from retinal 
neurodegenerative diseases. Taken together these studies offer a concise outlook on use 
of integrated systems science, molecular and imaging technologies as a needs-led 
innovation in ophthalmology and visual health. 
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CHAPTER 1.    INTRODUCTION 
 
 
Primary Open Angle Glaucoma 
 
 Glaucoma is a group of disorders that have in common a distinct type of optic 
nerve damage. The disease process is insidious such that central vision is usually not lost 
until the disease is advanced and thus many cases are left undiagnosed and untreated (1). 
For this reason, and others discussed below, glaucoma is a leading cause of blindness 
worldwide. The most frequently diagnosed types are primary open-angle, angle-closure 
and normal-tension, or low-tension, glaucoma. 
 
 Primary open angle glaucoma (POAG; OMIM 137760) is the most common form 
of glaucoma. It is a progressive optic neuropathy with characteristic changes to the optic 
nerve head and corresponding visual field defects (2, 3). Glaucoma affects 2% of 
individuals of European descent (4)and up to 10% of individuals of sub-Saharan African 
descent over 50 years of age (5, 6). The well-recognized risk factors associated with 
POAG include older age, elevated intraocular pressure (IOP), ethnicity, family history of 
POAG, myopia, and low diastolic perfusion pressure (7). 
 
 The main clinical features of POAG are an open iridocorneal angle and cupping 
of the optic-nerve head (or optic disk), as well as optic disc hemorrhages and 
parapapillary atrophy with corresponding loss of visual field (8, 9). From a 
pathobiological point of view, POAG is characterized by progressive retinal ganglion cell 
(RGC) death. RGC loss causes progressive deterioration of visual fields, leading to 
peripheral loss of vision. It is well known that elevated IOP plays a major role in RGC 
apoptosis and that reduction of elevated IOP often helps in slowing down the progression 
of degenerative changes in glaucoma. However only one-third to half of all glaucoma 
patients have elevated IOP at the initial stages (10-12). About 30-40% of patients with 
glaucomatous visual field defects are being diagnosed as having normal tension 
glaucoma (NTG) (13). Therefore, elevated IOP is now believed to be an important but 
not the only factor responsible for optic nerve damage. Text after this run-in head starts 
here and is styled Normal. 
 
 
IOP as a major risk factor 
 
 IOP is a significant factor in the diagnosis and management of glaucoma. It is the 
only known risk factor amenable to modification. It can be argued that elevated IOP is a 
major risk factor and is also considered to be a causative factor in glaucoma (14). There 
is a clear physiological association between high IOP and glaucoma. IOP can result from 
ocular trauma, inflammation, dysgenesis or other forms of obstruction of the aqueous 
humor drainage system in the trabecular meshwork of the iridocorneal angle by iris 
tissue, pigment or other deposits. Clinically, IOP is closely associated with visual field 
deterioration and optic nerve damage. It is estimated that the heritability for adult IOP 
range from 0.29 to 0.62 (15, 16). Linkage studies have shown two regions to be robustly 
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associated with IOP, one at 10q22 from a Tasmanian glaucoma pedigree, this region 
contains BMPR1A, a bone morphogenic protein receptor—interesting because Bmp4 has 
been implicated in increased IOP in mice (17). And another at 5q22 region which 
indicates WDR36 gene which codes for WD Repeat Domain 36 in a West African cohort 
(18, 19). A recent genome-wide association study (GWAS) for IOP also found associated 
loci, one of which (TMCO1 gene—transmembrane and coiled-coil domains 1) overlaps 
with a previously published POAG GWAS locus (20). Many large-scale multicenter 
clinical trials, including the Ocular Hypertension Treatment Study, the Early Manifest 
Glaucoma Trial, and the Advanced Glaucoma Intervention Study have shown that 
reduction in IOP effectively delays or prevents glaucomatous visual damage (21, 22). 
Therefore, lowering of IOP currently remains the only therapeutic option for mitigating 
the visual deficits associated with POAG. All current treatments of primary open-angle 
glaucoma are aimed at reducing IOP by medical or surgical means (23, 24). 
 
 
Role of RGCs in POAG 
 
 The cell bodies of RGCs constitute the innermost layer of the retina; they are the 
final output neurons of the retina. These neurons are fundamentally different from other 
retinal neurons because they receive input from the photoreceptors via bipolar and 
amacrine cells and have axons which exit the eye at the optic nerve head (ONH). The 
optic nerve collects all the axons of the ganglion cells and this bundle of more than a 
million fibers (in humans) then passes information to the brain. 
 
 In POAG, the RGC cell bodies and axons die, which leads to cupping of the optic 
nerve head. The mechanism of RGC damage is complex. The damage can occur due to 
many complementary mechanisms. Mitochondrial dysfunction has been proposed to play 
a key role in RGC loss in glaucoma (Kong et al., 2009; Lee et al., 2010; Osborne, 2010) 
it is the center stage for interactions between anti- and pro-apoptotic Bcl-2 family 
members (25). Excitotoxic injury has been also proposed to be involved in RGC cell 
death (26, 27). Most current hypothesis is that, excess glutamate binds to cell surface 
ionotropic glutamate receptors, primarily N-Methyl-D-Aspartate (NMDA) receptors 
(NMDAR), triggering massive Ca2+ influx and activation of pro-apoptotic signaling 
cascades in neurons leading to cell death (28, 29). Other studies show that RGCs die by 
apoptosis in models of acute optic nerve lesion (axotomy and crush) and experimental 
models of glaucoma (30, 31). Intrensic apoptotic pathways such as JNK/c-jun and Bcl-2 
gene family are known to play a major role in RGC cell death (32, 33). In addition, 
oxidative damage occurs in experimental models of optic nerve injury and in human 
glaucoma. For example, DNA damage as well as protein and lipid peroxidation products 
accumulate in the TM and retina from experimental animals with ocular hypertension and 
in POAG patients (34-36). The complement cascade is an important component of the 
innate immune system to recognize and eliminate pathogens and foreign material. A 
study showed that C1q, C3 or C4 undergo early upregulation in rat and primate glaucoma 
models, DBA/2J mice, and human glaucoma (37-39). Interestingly, reactive glial cells 
have emerged as mediators of RGC death in different injury modalities including ocular 
hypertension. Glial cells exacerbate excitotoxic damage, produce pro-inflammatory and 
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neurotoxic factors, and undergo detrimental changes that affects RGC viability. Although 
there have been substantial advances in our knowledge towards cellular mechanisms of 
how RGCs die in glaucoma, substantial hurdles remain to translate this knowledge to 
clinical practice for neuroprotection (40). 
 
 
Genetics of POAG 
 
 POAG is a genetically complex group of diseases, whose familial nature of 
POAG has been recognized for decades. POAG is the main type of glaucoma in most 
populations; and more than 20 genetic loci for POAG have been reported. About 5% of 
(POAG) is currently attributed to single-gene or Mendelian-recessive traits (usually 
early-onset forms of the disease), or may exhibit a heritable susceptibility consistent with 
complex trait inheritance (typically adult-onset forms of the disease). 
 
 Our modern understanding of the genetic architecture of POAG has evolved since 
the first gene for POAG, myocilin (MYOC), was mapped and identified. Since then, 
more than 20 genetic loci for POAG have been reported (41). The best known and 
studied loci are GLC1A on chromosome region 1q21-q24 spanning the MYOC gene (42), 
the GLC1E locus (region 10p14-p15) with the Optineurin (OPTN) gene (43), and locus 
GLC1G (region 5q22.1) containing the gene WDR36 (18). Other known genes with 
significant association with POAG/IOP include; TMCO1 (20), antisense noncoding RNA 
in the INK4 Locus (CDKN2B-AS1) (44), Growth Arrest-Specific 7 (GAS7) (20), 
Caveolin 1(CAV1/CAV2) (45), and SIX Homeobox 6 (SIX1/SIX6) (44). However, only a 
small number of patients with POAG have mutations in these genes. Currently, the 
genetic origins of the majority of glaucoma cases are unknown, as the known genes 
account for only a small fraction of heritable cases. The identification of genes (and their 
protein products) that can cause or contribute to glaucoma will help define the underlying 
pathophysiology as well as lead to the development of new DNA-based diagnostic tests 
and novel therapeutic approaches. 
 
Candidate gene studies 
 
 Family history is one of the risk factors of POAG, but the number of cases of 
POAG caused by single gene mutation accounts for only a small portion of all POAG 
cases. Numerous studies have focused on candidate gene approach based on either gene 
expression or the function or structure of specific proteins in multiple glaucoma-related 
tissues. This is simpler and cheaper than complete re-sequencing of candidate genes, and 
has been proposed as a powerful means to identify the common genetic variants that 
underlie complex diseases (46). The candidate gene approach has been successful for 
several inherited ocular diseases. However, most glaucoma cases involve low-penetrance 
risk alleles rather than mutations in known high-penetrant genes. This makes it difficult 
to select the variants of target genes in a large number of genetic variants. Since the 
fundamental pathophysiology of glaucoma is unknown, candidate gene studies will not 
sufficiently explore the genetic basis of the disease. Usually there is inconsistency in the 
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association and replication studies due to variations in the study design, diagnosis 
method, sample size and ethnicity. 
 
Genome-wide studies 
 
 GWAS approach has been performed in various common diseases and succeeded 
in identifying new susceptibility genetic regions including POAG. GWAS are case-
control studies, based on a comparison of unrelated but cases and control individuals 
from a population using single nucleotide polymorphisms (SNPs) that segregate with the 
disease or trait. A simple study design in GWAS includes four steps: (a) selection of a 
large number of individuals with the disease or trait of interest and a suitable control 
group; (b) DNA isolation, genotyping, and quality control; (c) statistical tests for 
associations between the SNPs and the disease/trait; and (d) replication of identified 
associations in independent population samples or experimental examination of 
functional implications to verify a true association. This type of analysis is very efficient 
and powerful in identifying causative genes, especially for complex diseases. GWAS 
have greater power to detect the effects of common variants, since linkage disequilibrium 
are measured in tens of thousands of bases (47). 
 
 Meguro et al. reported the first genome-wide significant (p = 2.5 × 10−9, odds ratio 
(OR) = 2.80) association for SNP rs3213787 in SRBD1 in the Japanese NTG population 
(48). Other POAG associated gene variants that GWAS identified include SNPs near 
CAV1 and CAV2 in an Iceland cohort (45), the caveolin genes have been postulated to 
influence transforming growth factor-beta (TGF-β) or nitric oxide signaling pathways 
involved in POAG pathogenesis. The association of the TMCO1 locus with POAG has 
been replicated in another GWAS for a Caucasian cohort (20). The ciliary body, 
trabecular meshwork and retina show abundant TMCO1 expression. However, its precise 
role in POAG pathogenesis is unclear. A recent study by Li et al. provided strong 
evidence of an association at the CDKN2B-AS1 locus (rs2157719, OR = 0.71, p = 2.81 × 
10−33), and also identified SNP rs1192415 in the CDC7-TGFBR3gene (1p22) showing 
significant association with POAG (OR = 1.13, p = 1.60 × 10−8) in the Asian, African and 
European populations, as well as SNP rs4894796 in FNDC3B (3q25.31) showing a 
significant association in Asians only (OR = 0.89, p = 7.93 × 10−8) (49). GWAS studies 
by Wiggs et al. and Osman et al. in the Caucasian POAG and Japanese POAG cases, 
respectively, have demonstrated a strong association of SNP rs10483727 located in the in 
the intergenic region between the SIX1 and SIX6 locus (14q23) (50, 51). SIX6 has been 
shown to express in the developing and adult human retina (52). 
 
 GWAS are advantageous since there is no need to include a specific disease 
model, which can allow identification areas of previously unsuspected pathogenesis. The 
pathogenesis of most cases of glaucoma, excluding those in which single gene defects 
have been identified due to contributions from many different polymorphisms. So 
likelihood of picking up an association depends on the ability to control for errors due to 
bias and poor phenotyping. GWAS need large numbers of cases and controls to identify 
the biological context in which statistically significant candidate variants act. This may 
reflect linkage disequilibrium between the SNPs identified and the true causative 
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functional variant. Therefore, fine mapping of the regions harboring the most significant 
statistical signals is need to be followed up by GWAS. These type of studies have 
significant cost implications. 
 
 
Systems Genetics Approach to Study Glaucoma 
 
 Systems genetics is an approach to understand molecular architecture that 
underlies complex traits. The multiple genetic and environmental factors that play a role 
in glaucoma make it difficult to identify individual genes linked to this disorder. Still, 
some genetic risk factors associated with forms of glaucoma have been identified in 
genes that code for proteins involved in known biological pathways. Despite this 
progress, determining which genes may be the most relevant to developing therapeutic 
interventions for glaucoma has proven exceedingly difficult. The major obstacles being 
that gene/disease associations reveal very little about the underlying basic molecular 
biology and any implicated gene variant explains only a small proportion of an 
individual’s overall risk for the disease. Recent advances in technology has provided 
tools that are capable of tracking genome-wide expression changes occurring in 
progressive pathological processes and diseases such glaucoma. It is becoming 
increasingly evident that the application of network-based genetics or systems genetics 
approaches can provide insights into not only the roles of individual genes or 
developmental pathways but also illuminate relationships between different levels of a 
biologic system, such as the genome, transcriptome, and phenome (53, 54). 
 
 Systems genetics is a relatively new branch of quantitative genetics that has the 
goal of understanding networks of interactions across multiple levels that link DNA 
variation to phenotype. Systems genetics involves an analysis of sets of causal 
interactions among classic traits such as IOP, networks of gene variants, and 
developmental/environmental/epigenetic factors. The main challenge is the need for 
comparatively large sample size and the use of more advanced statistical and 
computational methods and models. Genetic reference populations, which are genetically 
well characterized lines, are often used in systems genetics studies as a source to study a 
multitude of different phenotypes and to find the causal relations from networks of 
genetic correlations. 
 
 
Recombinant inbred strains 
 
 Recombinant inbred (RI) strains are a collection of genetic reference populations 
commonly used in genetic mapping of Mendelian and quantitative traits. Bailey and 
colleagues introduced the idea of using RI lines for detecting major-gene effects and to 
establish linkage (55-57). Conventionally, RI strains are developed by crossing two 
inbred parental strains. The inbred lines are mated repeatedly for 20 or more generations 
to warrant they are at least 99% inbred (55). Consequently, each RI line produced has 
two identical copies of each chromosome and is just a pure mosaic of the parental 
genomes. These homozygous lines contain the allele of either one or the other parental 
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strain. For a segregating trait, the linkage can be determined by matching the allelic 
pattern for the locus across the RI strains to the previously known markers. This is known 
as the strain distribution pattern (SDP). Generally, a qualitative trait is controlled by a 
single major gene, in contrast complex quantitative traits are influenced by moderate 
effects due to several genes. With the latest technologies, there has been a tremendous 
improvement in genotyping of RI strains with new markers and increasing data on SDP. 
RI strains are also used in identifying quantitative trait loci (QTLs) associated with 
quantitative traits (58-60). This idea was first introduced in late 1970s by correlating 
genetic marker information with quantitative phenotypes (61, 62). Classically, the 
Pearson correlation was used to measure association and the strength of this association 
was improved by using multiple markers and an interval mapping approach (63). The 
effectiveness of the RI strains depends on the size of the panel; the big panels tend to map 
the trait precisely. These strains are particularly useful for precise estimation of 
phenotypes associated with low to medium heritability. 
 
DBA/2J inbred strain as glaucoma mouse model 
 
 The development of new therapeutic drug targets for elevated IOP relies heavily 
on animal models, which represent a valuable tool for understanding both the progression 
and cause of glaucoma. The damage present at the time of diagnosis precludes the study 
of disease development from onset. Additionally, obtaining retinas at different pathologic 
states is difficult and is a limitation. Much of the progress in the study of glaucoma has 
been driven by the development of rat models is due to similar ocular anatomy to 
humans. They are readily available, easy to genetically manipulate and have a short life 
span. All these reasons make rodents a very attractive models to use as research tools for 
studying glaucoma. However, studies on mice have a distinct advantage over rats because 
these animals enable us to conduct complex genetic manipulations in order to study the 
function of crucial genes and pathways in glaucoma. 
 
 John et al developed DBA/2J as a mouse model of glaucoma that has become well 
established over the past few years (64). DBA2J mice develop elevated IOP and severe 
glaucoma like phenotype with age, followed by RGC death, and optic nerve 
degeneration. The IOP elevation is subsequent to an iris disease that deposits pigment in 
the ocular drainage structures. The iris transillumination defect is caused by mutations in 
two different genes- Tyrp1 and Gpnmb. The first is the mutation in the b allele of tyrosine 
related protein (Tyrp1b). Tyrp1 encodes a melanosomal protein that plays a role in 
enzymatic and structural functions in these organelles. The second mutant gene is Gpnmb 
which encodes a transmembrane glycoprotein found in multiple different cellular 
structures. The Gpnmb gene carries a stop codon mutation (GpnmbR150X). These 
mutations together lead to anterior chamber changes including pigment dispersion, iris 
transillumination, iris atrophy, anterior synechia, and elevated IOP. 
 
 A significant advantage in using DBA2J mice include the inbred nature of these 
mice, meaning that they have a fixed genetic background. Despite this, these mice exhibit 
a high degree of variability and asymmetry in developing the disease (65). 
Approximately 8-10% of the older DBA/2J mice have a combination of one normal, non-
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diseased retina and optic nerve, and one eye undergoing complete degeneration. Also, the 
relevance of TYRP1 and GPNMB to human glaucoma is controversial since no exonic 
mutations in either gene have been found in human glaucoma patients (66, 67). The 
unusual interplay of the Tryp1 and Gpnmb genes in initiating the anterior chamber 
disease is not related to POAG in humans. 
 
BXD strains 
 
 The largest and best-characterized murine reference panel is the BXD family of 
RI mouse lines (68) (Figure 1-1). The first of BXD lines from 1-42 were produce by 
researchers at Jackson laboratory and lines 43-100 were produced at University of 
Tennessee Health Science Center led by Dr. Robert Williams. The new set of BXD 
strains from BXD 43-108 were produced from advanced intercrosses, which makes them 
highly recombinant. These advanced intercross lines contain twice as many 
recombinations as the older BXD strains. The complete genomic sequence data of both 
the parents are publicly available (www.genenetwork.org).  
 
 The BXD strains are well suited for integrating data across multiple phenotype 
domains spanning molecular, morphological, physiological, and behavioral traits. BXDs 
have been used extensively in genetic and genomic studies of the eye and central visual 
system (69-71). The DBA/2J strain of mice is one of the parental strains of the BXD 
family. It closely mimics human hereditary pigmentary dispersion glaucoma. The greatest 
utility of this BXD family is that it can be used to map the chromosomal positions of 
sequence variants that cause differences in gene expression. Furthermore, reproducibility 
of eQTLs in the BXD family and in an F2 cross between the same parental strains has 
been reported to be very high (72).. Over the last two decades, the BXD family has been 
exploited to study the genetics of immune function and infectious disease (73, 74). It has 
also been used in behavioral and neuro-pharmacological research (75, 76). The eyes and 
retinas of this BXD family have also been well studied for more than a decade, and we 
now possess extensive cytological and morphometric data on their eyes and retinas that 
can be studied with reference to differences in gene expression. Due to the fixed 
genotypes of each BXD strain and the availability of massive databases of expression 
data it is possible to study correlations between a phenotype and genotypes. We can also 
study associations between two or more genes and identify upstream genetic regulators. 
 
 
Genetic dissections of genomic data 
 
QTL analysis 
 
 A forward genetics approach that is frequently used for studying complex traits in 
animal models is called QTL mapping. QTL analysis is a statistical method used to 
measure a particular quantitative trait across a genetically diverse population and 
screening for associations between genotypic and phenotypic variation (77, 78). The 
main purpose is to detect the polymorphisms underlying the phenotype of interest by 
scanning for alleles that co-vary with the traits. The regions of the genome that show a  
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Figure 1-1. BXD breeding scheme 
 
All BXD lines were derived by crossing C57BL/6J and DBA/2J parents. The resulting 
heterozygous F1 individuals were again crossed to generate genetically diverse but non-
reproducible F2 animals. These F2 progeny were iteratively inbred until generation F20+, 
at which point each line represents a unique mosaic of B6 and D2 alleles. 
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significant association with a phenotype are considered QTL. In short, the mapped QTL 
is the implicated region harboring a single gene that affects an associated phenotype. 
However, it is possible that a QTL may harbor or be controlled by multiple genes, non-
coding RNA (ncRNA) species, epigenetic mechanisms, or in combinations. Markers like 
SNPs and microsatellites are used for genotypic distinctions (79). Many QTL mapping 
studies have been carried out in human populations, but due to the excessive non-genetic 
variance contributed by each subject’s unique environment and life experiences, it 
presents a tremendous amount of noise (80). In contrast, mice are a highly attractive 
model for the purpose of dissecting complex traits. Mice are small in size, they have 
relatively low maintenance costs and short gestation period. With increasing 
advancement in technology there is an ever-expanding arsenal of genetic tools. QTL 
mapping studies are primarily conducted using inbred strains of mice and their various 
inbred lines (81). 
 
 The following are the four steps to achieve QTL mapping; the first step is to 
measure variation in a quantitative trait in a genetic reference population such as inbred 
mouse strains. The prerequisite is to have the quantitative traits that show phenotypic 
variability among the inbred strains. The phenotypic variation (VP) is due to the genetic 
(VG), environmental factors (VE) and interactions between them. The higher the variation 
due to genetic factors, the better is the mapping resolution of QTLs. The second step is to 
determine the heritability of the observed phenotypic variation. Heritability (H2) you an 
estimation of the genetic contribution to variation in phenotypic trait. It is calculated as 
the ratio of phenotypic variance that is due to genetic factors to the total variance 
(Equation 1.1). 
 
                                            H2 = VG/VP where VP = VG + VE                                 (Eq. 1.1) 
 
The third step is to proficiently collect the phenotype and genotype data from the inbred 
strains. The phenotype is any measurable or quantitative trait and genotype are various 
markers such as SNPs or copy number variants (CNVs). Such genotype markers are 
unique for individual strains and follow a particular strain distribution pattern. The fourth 
step is to generate a linkage map and perform the statistics generating a QTL. The most 
commonly used methods for doing a linkage analysis are- regression method, likelihood 
method, variance component method and the Bayesian method. For our study, we use 
GeneNetwork (http://www.genenetwork.org/webqtl/main.py) , which utilizes interval 
mapping to estimate the position of QTLs across a chromosome (60, 71, 76, 82). The 
significant linkage between the phenotypic trait and genotype is generated by using 
permutation test and by calculation of the likelihood ratio statistic (LRS). 
 
Expression QTL 
 
 Technological advancement has enabled us to use systems-level approach in 
identifying disease-associated genes using gene mapping methods and high throughput 
molecular data. QTL mapping methods were previously used for classical physiological 
or behavioral phenotypes, but now we can identify QTLs for genetic factors influencing 
high-throughput measures of transcript, protein and metabolite. This approach of 
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mapping effects of genetic variation on gene expression has been utilized in numerous 
studies in humans (83-85), mice (82, 86)and other organisms. Collectively, the regions of 
genome (loci) in which gene expression level is influenced by specific genetic variation 
are termed expression quantitative trait loci (eQTL). eQTL analysis provides an 
understanding of how changes in the genome affect transcript expression levels, 
providing further insight into how transcripts regulate disease. Typically, in eQTL 
mapping, regulatory variants have been commonly divided into cis or trans acting QTLs 
depending on their location and mechanism by which they affect gene expression. In the 
classical definition, cis-eQTLs refers to genetic variants that affect expression of a locus 
on the same DNA molecule, thus in allele-specific fashion. In contrast trans-eQTLs are 
expected to affect gene expression in an allele independent manner. Much of the variation 
at the genomic level that affects a trait occurs by cis-acting sequence differences. Trans-
eQTLs usually have smaller effect sizes and seem to be more tissue-specific than cis-
eQTLs (86, 87), thus complicating their detection. 
 
 
Application of Flow Cytometry in Eye 
 
 Flow cytometry is an analytical method that measures optical and fluorescence 
characteristics of single cells (or any other particle, including nuclei, microorganisms, 
chromosome preparations, and latex beads). Flow cytometry is rapid, reproducible, and 
sensitive, and can be applied to living cells in suspension, making it especially an 
attractive method in the study of cytological specimens. The ability to simultaneously 
measure multiple parameters on a cell-by-cell basis is perhaps the most powerful aspect 
of analytical flow cytometry. Characteristics that can be measured include cell size, 
cytoplasmic complexity, DNA or RNA content, and a wide range of membrane-bound 
and intracellular proteins. Cellular and physical properties, such as size or surface area 
(represented by forward angle light scatter) and internal complexity/granularity 
(represented by right-angle scatter) can resolve certain cell populations. The methodology 
relies on the use of antibodies conjugated to different fluorochromes, each with similar 
excitation wavelengths and different emission wavelengths (or “colors”). This allows 
several cellular properties to be measured simultaneously based on the mechanism of 
action of the fluorochromes associated with a dye, the specificity and sensitivity(88). 
Certain dyes such as fluorescein isothiocyanate [FITC], propidium iodide [PI], bind to 
specific proteins/lipids/nucleic acids to increase fluorescence. The fluorescence intensity 
may vary based on cellular physiological parameters such as pH, membrane potential, as 
well as enzymatic activity (fluorogenic substrates) such as esterases, peroxidases, and 
peptidases. 
 
 
Instrumentation 
 
 Flow cytometers comprise three main systems: fluidics, optics and electronics. 
Inside a flow cytometer, cells in suspension are drawn into a stream created by a 
surrounding sheath of isotonic fluid that creates laminar flow, allowing the cells to pass 
individually through a sensing point which is called the hydrofocus point. At the sensing 
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point, a beam of monochromatic light, usually from a laser, intersects the cells and 
produces the fluorescence emission. Emitted light is scattered in different directions and 
is collected via optics that directs the light to a series of filters and dichroic mirrors that 
isolates particular wavelength bands. The light signals are detected by photomultiplier 
tubes and converted into electrical signals by the optical and electronics system. The 
electric signals are converted into numeric data by different algorithms contained in the 
data acquisition component. Resulting data is analyzed using as additional software and 
represented in either single or two dimensional plots. 
 
 
Flow cytometry application in ocular diseases and retinal cell biology 
 
 A growing body of literature supports the application of flow cytometry in many 
fields of research such as immunology, cancer, cell biology, stem cell and biomolecular 
screening (89-91). Its application is not limited to just basic research where they are used 
for performing tasks that require analytical precision and high throughput. Flow 
cytometry instrumentation plays a key role in hospital and medical centers, where they 
are widely used for clinical diagnosis. However, in spite of the breadth of applications 
straddling many fields, the use of flow cytometry in neuroscience has been largely 
unexploited; being perceived as challenging and has seen only a steady increase in 
interest until recent years. Over the last decade, flow cytometry has proved useful in 
studying neuronal population in brain, CNS and eye (92, 93). Increased awareness of the 
quantitative and overall analytic potential of flow cytometry has recently encouraged its 
more widespread use in ophthalmology. 
 
 The analysis of retinal cells by flow cytometry in basic and clinical vision 
research is becoming more common in recent years. Cousins et al. identified and 
analyzed antigen-activated lymphocytes and their role of infiltrating immune effectors in 
ocular inflammatory disease using flow cytometry. They distinguished activated T and B 
lymphocytes from mouse eyes (94). Flow cytometry was also used later by Davis et al. to 
diagnose intraocular lymphoma and ocular inflammatory disease using patient vitreous 
specimens (95). Researchers have also utilized this technique to investigate HLA-DR on 
conjunctival epithelial cells from patients with cystic fibrosis using monoclonal 
antibodies to HLA-DR (96). Another example is in dry eye disease where Chen et al. 
used this analytical method to delineate the CD4+T-cell populations in normal, acute 
DED, and chronic DED mice (97). Flow cytometry of vitreous fluid samples has proven 
useful in the diagnosis of intraocular lymphoma, a subset of primary CNS lymphoma 
(98). A retrospective study of 20 patients with suspected intraocular lymphoma on slit 
lamp examination, 7 of 10 patients diagnosed with intraocular lymphoma by vitrectomy 
had positive flow cytometry findings (99). Flow cytometry had higher positive and 
negative predictive values compared with cytology. Several other retinoblastoma studies 
have looked at cell cycle regulation, proliferation and apoptosis using flow cytometry. 
(100-102) 
 
 Many laboratories have used standard intracellular or surface markers to identify 
neuronal cell types in the retina. In 2011, Samuel et al. used antibodies against recoverin 
 12 
to detect photoreceptors, syntaxin for amacrine, Chx10 for bipolar, PKC for rod bipolars, 
Thy1 for RGCs (103). They were able to identify changes the surface marker levels in 
these cell types due to age related changes. A similar study by Portillo et al. identified 
microglia/macrophages, endothelial cells, astrocytes, photoreceptors, ganglion neurons 
and Müller cells using CD11b, CD31, glial fibrillary acidic protein, rhodopsin, Thy1 and 
vimentin, respectively in mouse retinas (104). Apart from identifying subtypes of cells, 
one can also assess viability and damage in neuronal cells. Chang et al., measured 
viability and damage using BrdU, in small, medium and large RGCs in rats after eye 
injury by N-methyl-D- aspartic acid (NMDA)-injury. They identified the RGCs using 
Fluoro-Gold (FG) and were able to determine the size of the RGCs using flow cytometry. 
The damage was assessed using FG vs Thy1 intensity (105). The most common 
application of flow cytometry is assessment of toxicity, apoptosis and oxidative stress. 
 
 Another utility of FACS is the ability to quantify specific neuronal populations. 
Few successful attempts have been made in past, Kennedy et al. performed a simple 
technique to quantify rod outer segment phagocytosis in cultured RPE cells using FITC 
labeled rod outer segment to tag rod photoreceptors (106). Srinivastava et al. analyzed the 
RPE cell line ARPE19, human skin fibroblasts and human corneal epithelial cells by 
determining RPE65 protein expression and epithelial and fibroblast proteins (107). By 
focusing on identification of novel surface markers we can isolate subpopulations of 
retinal cells using Fluorescence-activated cell sorting (FACS). FACS of live cells 
separates a population of cells into sub-populations based on fluorescent labeling. Using 
FACS, Xu et al., isolated CD133+CD44+ retinal cells to study cell type composition of 
retinoblastoma tumors in mouse (108). Similarly, Feodorova et al., used size based 
inclusion method to isolate rod perikarya from adult mice, based on their high backscatter 
of heterochromatin in their nucleus (109). Lakowaski et al., used combination of five cell 
surface markers to facilitate the isolation of photoreceptor precursors, with a phenotype 
CD73(+)CD24(+)CD133(+)CD47(+)CD15(−) from three-dimensional model of retinal 
differentiation from mouse embryonic stem cells (110). Apart from these, flow cytometry 
and FACS can be utilized in many other domains and new applications have been 
developed in ophthalmology, for investigating ocular surface biology and 
pathophysiology. 
 
 Flow cytometry has also proved useful in studying glaucoma-associated changes 
in the eyes. Liu et al. have used flow cytometric study to assess the amount of 
inflammatory cells or cellular debris induced by lase iridotomy, which is a treatment 
method for pupillary-block glaucoma (111). A similar study by Cvenkel et al., 
determined the levels of IL-8, IL-1B, IL-6, IL-10 in aqueous humor of patients who 
underwent antiglacomatous surgery by flow cytometry (112). One of the implications of 
pathological changes associated with glaucoma is oxidative stress which leads to 
mitochondrial dysfunction. McElnea et al. examined those changes in human lamina 
cirbrosa cells from glaucoma donors. They evaluated mitochondrial membrane potential 
(MMP) and intracellular calcium [Ca2+] levels by flow cytometry using the JC-1 
(5,5′,6,6′-tetrachloro-1,1′,3,3′-tetrabenzimidazolecarbocyanine iodide) and fluo-4/fura red 
probes respectively (113). John and colleagues utilized flow cytometry to demonstrate the 
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natural deficiency of CD94 that underlies the DBA/2J mice, concluding it is not a 
pathogenic factor for glaucoma progression (114). 
 
 
Research Aims 
 
 
Aim 1: To identify the candidate gene that modulates IOP in mouse and test 
translational validity of the mouse candidates using the cohorts of human glaucoma 
patients 
 
1. Which gene variants modulate IOP in BXD mice strains? 
2. Do mouse candidate genes translate to human glaucoma patients?  
 
 
Aim 2: To identify and validate regulator of Sncg in primary mouse RGCs 
 
1. Can we use systems genetics to identify upstream modulator of Sncg? 
2. Can we combine systems genetics with other molecular techniques to validate the 
candidate gene? 
 
 
Aim 3: To isolate and validate primary murine RGCs from healthy and 
recombinant inbred mouse model of elevated IOP 
 
1. Can we isolate primary murine RGCs using flow cytometry? 
2. Can we apply this protocol to isolate RGCs from mouse model of glaucoma? 
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CHAPTER 2.    SYSTEMS GENETICS APPROACH TOWARDS UNCOVERING 
THE GENE MODULATORS OF IOP 
 
 
Introduction 
 
 Our aim was to identify new candidate gene variants for high IOP and to apply 
systems genetics approach to identify networks of genes that are critical for IOP. In this 
study we have systematically measured IOP across a large subset of BXD strains at 9.1-
13 months of age. These quantitative measurements have been deposited to an open-
access web service for systems genetics (www.genenetwork.org). We identified 
candidate gene variants by stringent stepwise refinement based on eQTL mapping, 
correlation analyses (direct and partial Pearson test) and single nucleotide polymorphisms 
(SNPs). We combined mouse SNPs with human GWAS glaucoma cohorts from 
GLAUGEN/NEIGHBOR consortium database in an effort to identify and validate any 
causal SNP within candidate genes. Here, we report for the first time a systems-genetics 
analysis of the genetic components regulating IOP (Figure 2-1). 
 
 
Methods 
 
 
BXD strains 
 
 IOP study: A total of 545 mice were used in this study Age 9.1-13 months (548 
mice from 66 BXD strains) Appendix A, Table A-1. The gender distribution was 
relatively equal with 313 females and 235 males being included. All procedures 
involving mice were approved by the Animal Care and Use review board of UTHSC and 
followed the Association of Research in Vision and Ophthalmology (ARVO) Statement 
for the Use of Animals in Ophthalmic and Vision Research in addition to the guidelines 
for laboratory animal experiments (Institute of Laboratory Animal Resources, Public 
Health Service Policy on Humane Care and Use of Laboratory Animals). Animals were 
housed under cyclic light (12 hour on: 12 hour off) with 35% humidity in a specific-
pathogen free (SPF) facility at UTHSC. Animals were fed a 5% fat Agway Prolab 3000 
rat and mouse chow (Breeder Chow, Teklad) and water ad libitum. 
 
 
IOP measurement 
 
 IOP was measured using the induction–impact tonometer (Tonolab tonometer, 
Colonial Medical Supply, Franconia, NH) for rodents according to the manufacturer’s 
recommended procedures. For measuring the IOP, the tonometer was fixed in a vertical 
position to a support stand by means of clamps. The mouse was gently restrained by hand 
on an adjustable stand, and the eye was oriented in such a way as a distance of 1–4 mm 
was maintained between from the tip the probe to the cornea of the eye. Six consecutive 
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Figure 2-1. Illustrated summary 
 
A systems genetics based study to identify and validate genetic modifiers of IOP using 
the enlarged BXD family of strains in combination with human GWAS glaucoma 
cohorts. In future, this will pave the way for improved drug development tailored to 
individual genotypes for POAG. 
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IOP readings were averaged. IOP readings obtained with Tonolab have been shown to be 
accurate and reproducible in different mouse strains, including DBA/2J (115). 
 
 
Identification of significant genes for IOP in mouse and human 
 
 IOP data generated from 9.1-13 months old BXD strains was integrated into the 
GeneNetwork database. The identification and mapping of phenotypic QTL (pQTL) was 
performed by linking trait data to genotypes at known genetic marker loci using the 
WebQTL module on GeneNetwork (http://www.genenetwork.org/). Genome wide 
significance levels were estimated by performing 2000 permutations based on our 
published methods (Lu et al., 2011a; Lu et al., 2011b; Swaminathan et al., 2013). This 
analyses produces a LRS score, providing us with a quantitative measure of confidence of 
linkage between the IOP and SNP markers. For the identification of single QTLs, interval 
mapping analyses were performed across all chromosomes. The parental strains were 
included in all mapping analysis. Composite interval mapping was performed for IOP at 
9.1-13 months, choosing genetic markers with highest LRS at the single QTL region or 
interacting loci from pairwise interaction scans, by factoring out of the effect of the pre-
eminent QTL the power to identify secondary QTLs on other chromosomes increased. 
 
 Human Genome-wide genotype data were obtained from the NEI Glaucoma 
Human Genetics Collaboration (NEIGHBOR) and the Glaucoma Genes and Environment 
(GLAUGEN) consortia, containing whole genome genotypes for 2170 cases and 2347 
controls. 495,132 SNPs were analyzed for GLAUGEN and 523,528 SNPs for 
NEIGHBOR (116). Logistic regression to assess the association between individual SNPs 
and POAG was done using PLINK v1.07. The human GWAS significance values were 
Bonferroni corrected for multiple comparisons using the total number of homologous 
genes compared and the number of tests used. 
 
 
eQTL analysis of IOP candidate genes 
 
 In this study, we aimed to infer causal mechanisms for IOP variation in BXD. 
Observing difference in gene expression that result from variants in the identified 
genomic region increases the confidence that this locus harbors causal candidates 
underlying the IOP peaks. Therefore, we chose to restrict our candidate search to the 
genes located in significant eQTL region for IOP. Candidate gene was identified using 
the GeneNetwork/UCSC Genome browser. Gene expression can be used as a micro trait 
to map regulatory eQTLs for the differences in mRNA expression levels over the panel of 
BXD lines since it’s a heritable trait. Whole eye expression levels were used as 
quantitative traits and implemented into interval mapping analyses to identify regulatory 
loci. The HEI Mouse Eye Dataset contains the data analysis of 221 Affymetrix M430 2.0 
arrays (Affymetrix, Santa Clara, CA). This database presents the whole eye transcriptome 
profiles of 80 strains of BXD mice aged between 2 and 4 months (117). Whole eye 
database was used since IOP modulation is facilitated by tissues in anterior chamber of 
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the eye. eQTL for a specific transcript was denoted cis-QTL if the associated marker was 
localized within a 10 Mb distance of the gene position. 
 
 
Immunohistochemistry 
 
 Mouse and human donor whole eye sections (10 μm) were blocked with 10% 
normal goat serum in PBS containing 0.25% triton X-100 for 30 min at room 
temperature, then incubated overnight at 4°C with the anti-CACNA2D1 primary antibody 
(Bioss Antibodies, Woburn, MA) diluted in the same buffer. After three washes with 
PBS, slides were incubated at room temperature for 2 hours with Alexa-Fluor-488-
conjugated secondary antibody (Invitrogen, Waltham, MA) and TO-PRO-III iodide 
(1:4000; Invitrogen) as a nuclear counterstain, washed with PBS again, and mounted with 
Vectashield anti-fade mounting medium (Vector Laboratories, Burlingame, CA). 
Sections were viewed and images were obtained using a Nikon C1 confocal microscope 
(Nikon, NY) within the Imaging Core Facility in the Hamilton Eye Institute. EZ-C1 free 
viewer software was used for image acquisition and processing. 
 
 
Statistics 
 
 To determine how much of the variation in candidate gene across the cohort was 
due to genetic effects, we calculated the heritability of the candidate gene using the 
formula of Hegmann and Possidente based on our published methods. Pearson product-
moment correlations were calculated using the Correlation matrix tool available in 
GeneNetwork. Pearson correlation measures the strength of a linear association between 
two variables and is denoted by r, which in our case is IOP (mmHg) and Cacna2d1 
mRNA expression. Within-strain and between-strain variances were calculated with 
analysis of variance (ANOVA) using SAS 6.0. 
 
 
Results 
 
 
Study design for genetics of IOP 
 
 We measured IOP in 66 strains of BXD including both males and females 
Appendix A-1, Table A-1. IOP was measured at 9.1-13 months of age. One of the 
advantages of measuring IOP at 9.1-13 months of age is that at this stage of life span 
these mice strains have already developed high IOP and the process of optic nerve 
damage has started. The main advantage of the genetically diverse BXD over non-inbred 
strains (such as an F2 intercross) is that the heritability of a trait can be accurately 
measured and reproduced since the strains lack heterozygosity (Figure 1-1). The 
differences among the isogenic strains is essentially due to genetic effects whereas 
differences within the strains is due to environmental effect (118). BXD strains serve as a 
tool for mouse genetics due to the conservation of the mammalian physiology. 
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BXD family has a wide variation in IOP 
 
 Since glaucoma is a complex disease caused by the combined effect of genetic 
and environmental risk factors we improved the power and precision of QTL mapping 
studies by including large number of strains (i.e genotypes) in the genetic study of IOP 
using BXDs. Among strains IOP varied (Figure 2-2) with BXD38 having the lowest IOP 
of 9.60.92 (mmHg SEM) and BXD44 having the highest at 21.821.67. The average 
IOP among all BXDs was 15.670.29. The parental lines, C57BL/6J and DBA/2J, had 
IOP levels of 15.220.77and 16.84 0.70, respectively (Figure 2-2). Heritability was 
calculated as the ratio of the within-strain variance to total sample variance. Based on our 
previous published study (119), heritability (h2) for IOP for BXDs at 9.1-13 months 
averaged to ~0.31. This value implies that 31% of the total trait variance is attributable to 
genetic factors and is comparable to that of other ocular traits to which QTL mapping has 
been applied successfully. The more heritable a trait, the higher the likelihood it will map 
to significant QTLs. Consistent with this significant heritability value, IOP becomes a 
particularly attractive trait for genetic dissection. Interestingly, Tyrp1 and Gpnmb 
genotypes did not influence IOP in BXD strains at 9.1-13 months (Figure 2-3A). There 
was no statistically significant correlation between the IOP and those genotypes (Figure 
2-3B). IOP in BXD strains at 9.1-13 months has no statistically significant sex 
differences and no strong correlation between males and females. They fall within 95% 
confidence interval (Figure 2-4). This indicates that IOP could be a phenotype where 
variation cannot be reliably attributed to genetic factors (i.e., variation is due to 
environmental or technical influence). 
 
 
QTL on Chr5 link causal loci for IOP 
 
 We mapped the variation in IOP to a narrow locus at the distal tip of Chr 5, 
peaking at or beyond reference SNP rs13478120 (LRS=19.6, LOD=4.25, Figure 2-5), 
which corresponds to human Chr 7:81,946,444 bp to 82,443,798 bp. IOP does not map to 
either Tyrp1 or Gpnmb locus (Figure 2-6). Therefore, polymorphisms within this QTL 
must be modulating IOP at 9.1-13 months of age. 
 
 
Initial identification of candidate gene in the Chr 5 QTL region 
 
 To determine the candidate gene variants that modulate IOP we used the 
following criteria:  
 
1. Pearson correlation analysis 
2. partial correlation analysis 
3. location within confidence intervals of murine QTLs 
4. expression in the eye 
5. gene size 
6. true cis modulation of candidate genes in eye and/or presence of coding 
differences segregating among progeny
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Figure 2-2. IOP levels across BXD strains and parental strains 
 
Rank-ordered IOP levels across the BXD recombinant inbred family. BXD strains and parental strains are represented in grey and 
black bars, respectively. Values denote IOP levels on mmHg scale (meanSEM). 
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Figure 2-3. Tyrp1 and Gpnmb genotypes do not influence IOP 
 
(A) BXD strains carrying wild type alleles of both Tyrp1 and Gpnmb (WT/WT; Blue 
bar), mutant of Tyrp1 and wild type allele of Gpnmb (MUT/WT; green bar)., wild type of 
Tyrp1 and mutant allele of Gpnmb (WT/MUT; yellow bar), mutant alleles of both genes 
(MUT/MUT; red bar). (B) The plot shows average IOP versus genotypes with or without 
Tyrp1 and Gpnmb mutations in BXD strains at 9.1-13 months (n = 66). 
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Figure 2-4. Correlation of IOP for females and males at 9.1-13 months 
 
IOP in BXD strains at 9.1-13 months has no statistically significant sex differences and 
no strong correlation between males and females. 
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Figure 2-5. QTL mapping for IOP 
 
A significant QTL for IOP is present on chromosome 5. Red and gray horizontal lines dictate significant and suggestive thresholds, 
respectively. 
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Figure 2-6. QTL mapping for Tyrp1 and Gpnmb in BXD strains eyes 
 
A significant QTL for Tyrp1 is present on chromosome 6. A significant QTL for Gpnmb is present on chromosome 4. Yellow bar 
represents the frequency of the peak QTL. Red and gray horizontal lines dictate significant and suggestive thresholds, respectively. 
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7. plausible biological link to IOP and glaucoma 
8. presence of SNPs in the GLAUGEN and NEIGHBOR human GWAS studies of 
POAG and IOP  
 
 To identify the gene candidate, we first performed Pearson correlation by 
generating a list of top 500 correlates of IOP within the whole eye database based on our 
published methods (82). Out of top 500 gene correlates, Cacna2d1 (Pearson correlation 
value: r=0.440; p=0.0003) and Sema3e (Pearson correlation value: r=0.295; p=0.02) were 
the only two genes located in the QTL peak at Chr5 (Figure 2-7). To identify the best 
candidate, we performed partial correlation analysis (120) (Figure 2-8). By controlling 
for the genetic variability associated with QTL peak at Chr5, we were able to identify a 
single candidate, CACNA2D1 (partial Pearson correlation value: r2=0.331; p=0.0093). 
CACNA2D1 is known as Calcium Channel, Voltage-Dependent, Alpha 2/Delta Subunit 1 
(Figure 2-9). The gene encodes for a preproprotein which is cleaved into multiple chains 
that comprise the alpha-2 and delta subunits of the voltage-dependent calcium channel 
complex. Calcium channels mediate the influx of calcium ions into the cell upon 
membrane polarization (121). Mutations in this gene can cause cardiac deficiencies, 
including Brugada syndrome and short QT syndrome (122) (Figure 2-10).  
 
 
Genetic polymorphisms underlying variation in Cacna2d1 contribute to changes in 
IOP 
 
 The expression of Cacna2d1 transcript in the whole eye among BXD strains 
varied (Figure 2-11) with BXD71 having the lowest Cacna2d1 gene expression of 
6.910.24 (expression Log2  SEM) and BXD48a having the highest at 9.710.33. The 
average expression among all BXDs was 8.350.37. The parental lines, C57BL/6J and 
DBA/2J, had Cacna2d1 expression levels of 9.5 0.07and 7.54 0.15, respectively 
(Appendix A, Table A-2). The simple interval map shows a significant cis-eQTL for 
Cacna2d1 on proximal Chr5:14.324112 with in the 5Mb of gene location (Figure 2-12). 
The maximum LRS score of the locus was 143, which is equivalent to a LOD ratio of 
31.01. Cacna2d1 gene has a 69% variance, which is explained by the single peak QTL at 
Chr5. The majority of BXD strains with the D parental allele have low expression of 
Cacna2d1 in the eye, while those with the B parental allele have higher expression of the 
gene (Figure 2-13). Cacna2d1 is highly polymorphic in both mice and humans. We 
identified known genetic variability between C57BL/6J and DBA/2J strains in Cacna2d1 
gene and its flanking region within the eye using UCSC genome bioinformatics site 
(http://genome.ucse.edu) (Figure 2-14). We identified five synonymous coding SNPs 
within Cacna2d1 gene, 866 non-coding SNPs and 177 insertions/deletions, making this 
gene highly polymorphic (Table 2-1). These polymorphisms segregate among the BXD 
strains. Similarly, in humans, CACNA2D1 has 8801 exonic SNPs, 44 of which are non-
synonymous. There are also 7 CNVs and 5 InDels segregating in humans 
[http://www.genecards.org/cgibin/carddisp.pl?gene=CACNA2D1] (Table 2-2). 
 
 The next step in our analysis was to obtain SNP level p-values for association 
with GLAUGEN and NEIGHBOR human GWAS studies of POAG and IOP (116). 
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Figure 2-7. The screen shot depicts the Pearson correlation analysis using the tools available on GeneNetwork 
 
Pearson correlation analysis listed two genes- Cacna2d1 and Sema3e within the QTL peak. The genes highlighted in yellow depicts 
top candidate genes for IOP modulation at 9.1-13 months of age based on Pearson correlation analysis. 
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Figure 2-8. The screen shot depicts the partial correlation analysis using the tools available on GeneNetwork 
 
Partial correlation analysis listed only Cacna2d1 within the QTL peak. The genes highlighted in yellow depicts top candidate gene for 
IOP modulation at 9.1-13 months of age based on partial correlation analysis. 
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Figure 2-9. Zoomed-in view of QTL map for IOP 
 
A significant QTL for IOP is present on chromosome 5 between 14-19Mb. Cacna2d1 is 
the candidate gene located in the peak QTL. Black vertical line shows the location of the 
candidate gene. Red and gray horizontal lines dictate significant and suggestive 
thresholds, respectively.  
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Figure 2-10. Subunit structure of L type calcium channel with description. 
 
α1, β and  subunits are in blue. α2 and subunits are in red with a disulphide bond 
between them. α21is GPI anchored to the plasma membrane. 
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Figure 2-11. mRNA rxpression levels of Cacna2d1 across BXD strains and parental strains. 
 
Rank-ordered mean Cacna2d1 mRNA expression levels across the BXD recombinant inbred family. Values denote normalized 
relative expression levels on Log2 scale (meanSEM). 
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Figure 2-12. A significant cis-eQTL for Cacna2d1 is present on chromosome 5 at 14-19 Mb. 
 
Red and gray horizontal lines dictate significant and suggestive thresholds, respectively. The purple triangle indicates the location of 
Cacna2d1 within the mouse genome. 
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Figure 2-13. Cacna2d1 expression in whole eye of BXD strains attributable to the 
genotype 
 
Correlation between the trait values (here, Cacna2d1 expression levels) and the genotype 
at the peak location. The majority of BXD strains with the D parental allele have low 
expression of Cacna2d1 in the eye, while those with the B parental allele have higher 
expression of the gene. 
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Figure 2-14. UCSC Genome Browser illustration of the gene structure and location of SNPs associated with Cacna2d1 gene 
 
Graphic depiction of Cacna2d1 gene with SNPs on chromosome 5 of the mouse genome. Reference Sequence mRNAs are 
represented in blue and known mRNAs are represented in black. 
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Table 2-1. Summary of candidate gene Cacna2d1 in mouse 
 
Candidate 
Gene 
Probe Set I.D Gene 
Location 
Mean 
Expression 
Level 
Max LRS and 
Location 
Cis eQTL 
(Yes or No) 
SNPs and 
Indels 
P-Value 
Cacna2d1 1446324_at Chr5: 15,440,509-
15,880,329 bp 
8.5 143 Yes  Non-coding 
SNPs: 866 
 Synonymous 
SNPs: 5 
 InDels: 177 
2.43x10-5 
 
 
 
 
Table 2-2. Summary of candidate gene Cacna2d1 in humans 
 
Candidate 
Gene 
Location SNPs and Indels SNP 
I.D 
P-Value 
CACNA2D1 Chr 7: 
81,946,444-
82,443,798 
bp 
 Coding SNPs: 398 
 Non-coding SNPs: 
17,940 
 InDels: 45 
rs4732474 0.0075 
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Association analyses were carried out using the SNP genotypes of the CACNA2D1 gene 
and flanking regions. The results showed evidence of weak associations between 
rs1022418 (p=0.03; Odds ratio=1.17) of the CACNA2D1 and normal tension glaucoma 
subset as well as rs6467882 (p=0.04; Odds ratio=0.87) of the CACNA2D1 and high 
tension glaucoma subset. Furthermore, based on the inputted genotypes, rs4732474 of 
CACNA2D1 showed a genome wide nominal association with the combined normal 
tension and high tension glaucoma populations (i.e POAG). The p-value of rs4732474 
was 0.0075 and odds ratio was 1.14, which is significant at gene level. None of the SNPs 
remained genome wide significant after correction for multiple testing even when linkage 
disequilibrium structure of the SNPs was taken into account, however rs4732474 was 
significant at gene level since the p-value was less than 0.05. 
 
 
CACNA2D1 is localized in the mouse and human eye 
 
 To compile additional evidence to support our hypothesis, we performed 
immunohistochemistry (IHC) to determine the localization pattern of CACNA2D1 in 
mouse and healthy human donor eyes. In mouse retina, CACNA2D1 is prominently 
localized in the trabecular meshwork, ciliary body and ciliary muscle (Figure 2-15). 
CACNA2D1 immunoreactivity was also observed in the nerve fiber layer, inner 
plexiform layer and outer nuclear layer was also occasionally observed (Figure 2-15). 
Positive staining and localization of CACNA2D1 in the mouse eye was further 
corroborated by immunofluorescence microscopy analysis in human donor eyes (Figure 
2-16). 
 
 
Discussion 
 
 POAG is often regarded as ‘thief of sight’ and IOP is a highly heritable risk factor 
POAG, this makes is the only target for current glaucoma therapy (14). But the genetic 
factors which determine IOP are largely unknown. In this investigation, we have 
combined cutting edge methodologies of systems genetics, bidirectional studies using 
multiple species, meta-analyses and immunohistochemistry studies to identify a novel 
genetic modulator of IOP. We systematically explored sources of genetic variation in the 
IOP. We identified a novel QTL for IOP on chromosome 5. By combining our QTL 
analyses with expression correlation analyses, human GWAS and literature review, we 
identified a cis-regulated geneCacna2d1 that may enable a deeper understanding of 
IOP and glaucoma. 
 
 POAG has an insidious onset and low natural course hindering a definite 
diagnosis at an early stage. Diagnosis is usually non-uniform due to etiological and 
clinical heterogeneity of POAG. Due to this, the current gene-finding in POAG focuses 
on the adult-onset POAGs where relatively few people would be available to participate 
thus limiting the identification of large affected families for gene mapping by linkage 
analysis (123). These limitations fuel the need for the use of a genetic reference 
population of RI strains, from which diverse phenotypes and genotypes can be collected   
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Figure 2-15. Cellular localization of CACNA2D1 in C57BL/6J mouse eye 
 
Sections from C57BL/6J mouse anterior chamber angle and retina were labeled with 
antibodies against CACNA2D1. TO-PRO-III iodide staining labeled nuclei of all retinal 
cells (blue). Abbreviations: TM=trabecular meshwork; CB=ciliary body; CM=ciliary 
muscle; SC= schlemm's canal; GCL=ganglion cell layer; INL=inner nuclear layer; 
ONL=outer nuclear layer. Scale bar: 100μm. 
 
 
 
 
 
 
Figure 2-16. Cellular localization of CACNA2D1 in a human donor eye with no 
diagnosis of ocular diseases 
 
Sections from the anterior chamber angle and retina were labeled with antibodies against 
CACNA2D1. TO-PRO-III iodide staining labeled nuclei of all retinal cells (blue). 
Abbreviations: TM=trabecular meshwork; CB=ciliary body; CM=ciliary muscle; SC= 
schlemm's canal; GCL=ganglion cell layer; INL=inner nuclear layer; ONL=outer nuclear 
layer. Scale bar: 20μm. 
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and reproduced over time. Using the BXD RI genetic reference population, we found that 
IOP is highly heritable and variable, there was no gender influence in IOP at 9.1-13 
months. 
 
 To determine which candidate genes modulate IOP in the eye, we performed 
simple interval mapping. Our mapping studies in BXD mice indicate a single highly 
genome wide significant QTL on Chr5. Variation in IOP in the BXD family maps to Chr 
5 with a LOD of 4.0 and a 1.5 LOD confidence interval from 14.2 to 18.8 Mb (Pclo to 
A921504A21Rik). The effect size is +1.0 mmHg/per B allele. We pursued second strategy 
of Pearson and partial correlation analyses to corroborate the findings of our QTL 
analysis for Chr5. These results suggested that within this strong eQTL reside some 
transcripts that predominantly regulate IOP. We focused on one positional and 
biologically relevant geneCacna2d1located on Chr5 QTL peak. Cacna2d1 is the 
best candidate and is cis-regulated in BXD retinal data sets. This gene has shown to play 
key roles in modulating calcium uptake which is crucial for IOP in the eye (124). Tyrp1 
and Gpnmb gene mutations have been well known to develop iris transillumination defect 
in DBA/2J mice. However, based on our correlation analysis and previously published 
paper there was no correlation between the expression of these genes and IOP. Moreover, 
IOP did not map to either the Tyrp1 or Gpnmb locus (119). 
 
 Genetic variations are a major factor for inter-individual differences in disease 
susceptibility and response to environmental exposures. The great majority of DNA 
polymorphisms consist in SNPs. Most SNPs manifest in introns which may have no 
effect on the individual phenotypes. However, SNPs, though rarely being directly 
pathogenic, are frequently correlated to the occurrence of multigenic diseases. Both in 
mouse and humans Cacna2d1 has hundreds of SNPs and insertions/deletions, which 
makes it highly polymorphic. In humans, CACNA2D1 also contained a SNP with a p 
value reaching significance at the individual gene level in the GLAUGEN and 
NEIGHBOR human GWAS studies of POAG and IOP (SNP rs4732474, p=0.0075). 
Recently, a GWAS of Beaver Dam Eye Study revealed 7 regions of interest modulating 
IOP. One of the regions of interest is Chr7 which corresponds to CACNA2D1 gene and 
this region has suggestive association with IOP (11). Another study has shown human 
Chr 7 (i.e., 7q35-q36) to be associated with pigment dispersion syndrome (125). A 
common variant mapping to another calcium channel subunitCACNA1A, is associated 
with susceptibility to exfoliation syndrome (126). In this disease, there is a build-up of 
extracellular matrix deposits and pigment in the trabecular meshwork which can impede 
the drainage of AH from the eye thus resulting in elevated IOP and glaucomatous optic 
neuropathy (126). This provides further evidence support to our hypothesis that 
CACNA2D1 may modulate structure or function of calcium channels and contribute to 
modulation of IOP in glaucoma. Our immunohistochemistry data demonstrated that 
CACNA2D1 is localized in the ciliary body, trabecular meshwork and ciliary muscle as 
well as in the RGC bodies and axons. This observation was consistent in both mouse and 
human eyes. An interesting implication of this observation is that CACNA2D1 might be 
modulating IOP via the AH dynamics and is neuroprotective as well, although the 
mechanism by which this occurs is not known.  
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 CACNA2D1 encodes for the alpha2 delta1 subunit of the type L-type voltage-
dependent calcium channel. Calcium channels are responsible for the transport of calcium 
ions across cell membranes and play a key role in a cell’s ability to generate and transmit 
electrical signals. Calcium channels are ubiquitous and are responsible for the transport 
of calcium ions across cell membranes which plays a key role in a cell’s ability to 
generate and transmit electrical signals. They play important physiological roles in 
modulating the calcium balance in various tissues (121). In the eye, calcium plays a 
critical role in modulating the cleavage of calcineurin in response to elevated IOP, which 
inhibits pressure-induced RGC axon loss (127). In addition, calpains activate cyclin 
dependent kinase 5, which has also been implicated in POAG (128). Mishandling of 
intracellular calcium by glaucomatous trabecular meshwork cells may also contribute to 
its failure, leading to increased AH outflow resistance and elevated IOP (124). Excessive 
calcium influx is a major player of retinal cell death and a hallmark of pathological 
processes activated by retinal injury and disease (129). RGC loss due to dysregulated Ca 
channel signaling has been attributed to glutamate excitoxicity mediated by 
overstimulation of NMDA receptors, (130), activation of Ca2+ permeable TRP channels 
(131), defective calcium buffering stores (for example, mitochondrial dysfunction) (132), 
and excessive release of nitric oxide (133). Since functional deficits can occur early in the 
progression of glaucoma and other optic neuropathies, targeted Ca channel blockade may 
have a role to play in how optic neurpathies are treated. Understanding the role of 
CACNA2D1 in RGCs will provide a platform for future experiments investigating their 
contribution in retinal injury models. Because calcium channels play a role in the 
pathophysiology of glaucoma, systemic calcium channel blockers (CCBs) have been 
evaluated in a limited number of studies as plausible therapies for POAG (134). 
However, the results have been inconsistent, with some studies demonstrating that CCBs 
are highly effective in lowering IOP, protecting ganglion cells, increasing ocular blood 
flow and improving visual function, while others fail to replicate those results (134). It is 
possible that because CCBs target calcium channels, which are highly polymorphic, they 
will only be effective on a subset of the population.  
 
 Our study provides the first candidate geneCACNA2D1, to explain variation in 
IOP by combining the power of mouse quantitative genetics with human GWAS studies. 
This novel finding will lead to the development of new IOP-lowering therapy. In future, 
similar studies would enable us to identify glaucoma-associated genes and how these 
genes can be validated as functional targets, and how this will bridge the gap between 
data generation and effective drug target identification. 
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CHAPTER 3.    MULTIPRONGED APPROACH TO IDENTIFY AND 
VALIDATE A NOVEL UPSTREAM REGULATOR OF SNCG IN MOUSE RGC* 
 
 
Introduction 
 
 Glaucoma is the world’s leading retinal neurodegenerative disease that causes 
irreversible vision loss (135). Degeneration of RGC somas and their axons is a hallmark 
of its pathophysiology. Because it is a multifactorial disease, the degeneration of the 
RGC can be influenced by multiple affecters including physiological stress (i.e. oxidative 
stress, neurotransmitter toxicity (136), and/or ER stress-related chaperone proteins (137, 
138). Members of the synuclein family of proteins are chaperone molecules 
predominantly expressed in neurons (139). In diseases such as Alzheimer’s and 
Parkinson’s, mutant synucleins are key components of pathological inclusions (140, 141). 
Among the three known isoforms (, and ), a reduction in the expression level of -
synuclein (SNCG) in the retina and optic nerve head have been reported in glaucoma 
patients (139, 142). Recent studies have demonstrated a direct correlation between the 
reduced expression of Sncg mRNA and the loss of RGCs in various animal models of 
glaucoma (143). Collectively, these studies suggest that loss of SNCG is a putative 
marker of RGC degeneration, yet the molecular targets and biological relevance of 
aberrant SNCG expression remains largely unknown. 
 
 In the present study, we used C57BL/6J and DBA/2J mice, as well as the BXD RI 
family as a collective genetic reference panel to determine which gene(s) regulate Sncg 
expression in murine RGCs. We have also compared the localization pattern of Sncg and 
its upstream modulator in mouse and human donor retinae using immunohistochemistry. 
Using flow cytometry-based sorting, we isolated enriched RGCs and performed 
knockdown studies to validate our findings. The outcomes of our investigation may 
provide clues to understanding the molecular mechanisms that account for the 
degenerative changes in RGCs in glaucoma (Figure 3-1). 
 
 
Methods 
 
 
Human donor eyes 
 
 Human donor eyes were collected in accordance with the tenets of the Declaration 
of Helsinki and approved by University of Tennessee Health Science Center (UTHSC) 
Institutional Review Board (IRB). A human donor eye with a clinical diagnosis of 
glaucoma (age 67 years; female) and an eye from an age-matched control (with no  
                                                 
 
* Reprinted with permission from John Wiley & Sons. Chintalapudi SR, Morales-Tirado VM, Williams 
RW, Jablonski MM. Multipronged approach to identify and validate a novel upstream regulator of Sncg in 
mouse retinal ganglion cells. FEBS J. 2016 Feb;283(4):678-93. doi: 10.1111/febs.13620. Epub 2016 Jan 
18. PubMed PMID: 26663874. 
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Figure 3-1. Illustrated summary 
 
A combined study using systems genetics with flow cytometry and gene silencing to 
identify and verify the genetic regulation of Sncg in primary RGCs. This study provides 
clues to better understanding of disease mechanisms in glaucoma. 
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history of eye disease; age 83 years; male) were obtained from the Mid South Eye Bank 
and the Lions Eye Bank of Oregon in compliance with the Eye Bank Association of 
America's (EBAA) Medical Standards and Government Regulation. Both donors were 
free of sepsis and potentially transmissible disease. There was no evidence of high-risk 
behavior, HIV or hepatitis. Donor eyes were fixed in formalin within five hours of 
enucleation. The anterior segment structure was removed from both eyes and the fundi 
were photographed. Full thickness biopsies of the temporal retina of each eye were 
removed with a 5-mm diameter punch (Miltex, PA, USA). Retinae were carefully 
dissected away from the retinal pigment epithelium, choriocapillaris and sclera. 
 
 
BXD strains 
 
 A total of 73 strains of mice at approximately 8 weeks of age, including 69 BXD 
RI strains, parents and F1 crosses were used in this study. Both sexes were equally 
represented (117). All procedures involving mice were approved by the Animal Care and 
Use review board of UTHSC and followed the ARVO Statement for the Use of Animals 
in Ophthalmic and Vision Research in addition to the guidelines for laboratory animal 
experiments (Institute of Laboratory Animal Resources, Public Health Service Policy on 
Humane Care and Use of Laboratory Animals). Animals were housed under cyclic light 
(12 hour on: 12 hour off) with 35% humidity in a specific pathogen free environment at 
UTHSC. In our immunohistochemical analyses, a female BXD66 mouse aged ~12 
months are used as a model of glaucoma due to their elevated IOP (18.501.47 mmHg; 
unpublished observation but available on www.GeneNetwork.org) and high degree of 
optic nerve damage inclusive of many degenerating axons and gliotic scarring that are 
apparent on cross sections (unpublished observation but available on 
www.GeneNetwork.org). 
 
 
HEI Retina Database 
 
 The HEI Retina Database contains the data analysis of 346 Illumina Sentrix® 
Mouse Whole Genome-6 version 2.0 arrays (Illumina, San Diego, CA). This database 
contains the retinal transcriptome profiles of 80 strains of BXD mice aged between 2 and 
4 months (117). We used the ‘Normal HEI Retina Dataset’ that is available on 
GeneNetwork (www.genenetwork.org) to perform QTL analysis and define genetic 
networks. This data is globally normalized to produce arrays that have a mean of 8 and a 
standard deviation of 2.0 (70, 71). The GEO Dataset generated by Dr. Simon John and 
colleagues at the Jackson Laboratory (NCBI accession number GSE26299; Affymetrix 
platform; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26299) was 
normalized in the identical manner and uploaded onto GeneNetwork. This dataset was 
derived from retinae of DBA/2J mice with varying degrees of glaucomatous optic nerve 
damage (38). 
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eQTL mapping and heritability calculation 
 
 Simple interval mapping was carried out using the WebQTL module on 
GeneNetwork to identify any significant eQTL(s) that modulate Sncg expression. 
Genome wide significance levels were estimated by performing 2000 permutations. To 
determine how much of the variation in Sncg expression across the cohort was due to 
genetic effects, we calculated the heritability of Sncg using our published methods (59, 
69, 82){Lu, 2011 #261;Lu, 2011 #204;Swaminathan, 2013 #100}. 
 
 
Identification of candidate gene(s) 
 
 The partial correlation feature on GeneNetwork was used to identify any 
candidate gene that modulates Sncg expression in retina. A partial correlation is defined 
as the relationship between a primary variable and a target variable, while controlling for 
one or more other variables (120). In this case, the correlation between the expression of 
Sncg (primary variable) and the expression of candidate regulatory gene within the retina 
database (target variables) was measured after mathematically controlling for the 
markersrs8242766 (Chr1 at 172.981863) and rs4136041 (Chr1 at 177.366982)that 
straddle the trans-eQTL that was identified using simple interval mapping. By holding 
constant the genetic variation of this region, any residual biological variation more 
accurately reflects the correlation between the expression of the Sncg and the candidate 
regulatory gene(s). In essence, genes with false positive correlations are removed from 
the list of potential candidate modifiers. 
 
 
Immunohistochemistry 
 
 Human and murine retinal sections embedded in low melting point agarose were 
prepared following our published methods (144). Briefly, tissue sections were blocked 
with 10% goat serum and permeabilized with 0.1% Triton X-100. Anti-prefoldin 2 
(PFDN2; goat polyclonal IgG, Catalog number: sc-19834; Santa Cruz Biotechnology) 
and anti-gamma synuclein (SNCG; rabbit polyclonal IgG, Catalog number: GTX110483; 
GeneTex) were used per manufacturers conditions. Appropriate Alexa Fluor-tagged 
secondary antibodies (1:200; Invitrogen) and TO-PRO3 iodide (1:4000; Invitrogen) were 
used to indicate the presence of the antigens of interest and nuclei, respectively. Sections 
were viewed and images were obtained using a Nikon C1 confocal microscope within the 
Imaging Core Facility in the Hamilton Eye Institute. All microscope settings, including 
laser levels and gain, were held constant to allow for relative comparisons of signal 
intensity within and between experiments. 
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Enrichment of primary murine RCGs 
 
Cell suspension of retinae cells 
 
 C57BL/6J mice (80 mice at 5-8 weeks of age) were sacrificed by cervical 
dislocation followed by enucleation. Collected retinae were dissociated using enzymatic 
digestion containing papain (15 IU/mL papain, 5 mM L-cysteine and 200U/mL DNase I) 
in PBS.  Enzymes were inactivated by the addition of PBS/10% fetal bovine serum (FBS; 
Hyclone Laboratories, Inc.). The cell suspension was filtered through a Falcon 70 µM 
nylon strainer (BD Biosciences, San Jose, CA) and centrifuged at 1300 RPM for 5 
minutes at RT. Cells were resuspended in PBS/1% FBS and kept on ice until ready to 
use. Cell viability was assessed by trypan blue exclusion (145). 
 
Cell labeling 
 
 We used a 1:100 solution of an amine-reactive dye, Zombie Aqua (BioLegend), 
diluted in PBS to discriminate between live and dead cells. Prior to immunolabeling, cells 
were treated with 5 µL of anti-CD16/32 (FcR II/III block, BioLegend) to minimize non-
specific binding of antibodies. CD16/32 are also known markers for monocytes and 
macrophages. Aliquot of unlabeled retinal cells were used as negative control to 
determine the degree of autofluorescence and to control for voltages. The following 
isotype controls were used to confirm the specificity of primary and secondary 
antibodies: mouse IgG1 (clone MOPC-21, BioLegend) PE-Cy7, AF700, FITC PerCP-
Cy5.5 and rat IgG2b (clone RTK4530, BioLegend). The AbC Anti-Mouse Bead Kit 
(Life Technologies, Carlsbad, CA) was used as an instrument calibration and single-
fluorochrome reference. The following primary antibodies were used to label cells for 30 
minutes on ice: anti-CD90.1 PerCP-Cy5.5 (Thy1.1, clone OX-7, Catalog number: 
202516, BioLegend; exhibits no cross-reactivity with CD90.2) and anti-CD90.2 Alexa 
Fluor-700 (Thy1.2, clone 30-H12, Catalog number: 105320, BioLegend; exhibits no 
cross-reactivity with CD90.1) as a Pan-Thy1 marker; and anti-CD48 PE-Cy7 (clone 
HM48-1, Catalog number: 103424, BioLegend). Cells were enriched by FACS using a 
BD Biosciences FACSAria Cell Sorter (BD Biosciences). 
 
Sorting strategy 
 
 Live cells were gated by Zombie Aqua exclusion followed by Pan-Thy1 
positivity. Live PanThy1+ cells were selected based upon negative CD48 expression. The 
collected population of RGCs had the following phenotype: Live PanThy1+CD48neg cells. 
 
 
Flow cytometry analyses 
 
Intracellular straining 
 
 Cells were fixed for 1hr at 4°C using BD Cytofix/ Cytoperm™ Buffer (BD 
Biosciences). Anti-gamma synuclein (dilution: 1:100; GeneTex Inc.) and anti-prefoldin 2 
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(dilution: 1:100; Santa Cruz Biotechnology, San Diego, CA) antibodies were diluted in 
permeabilization buffer and incubated with cells for 1hr at 4°C. Alexa Fluor-568 goat 
anti-rabbit IgG or Alexa Fluor-488 donkey anti-goat IgG (Molecular Probes) were used 
as secondary antibodies. Cells were kept in PBS/1%FBS until ready for analysis. Data 
acquisition was performed on a BD LSRII Flow Cytometer (BD Biosciences) and 
analyses were performed using FlowJo vX10.0.6 (Tree Star, Inc., Ashland, OR). 
 
Cell proliferation studies 
 
 Sorted, enriched-primary RGCs were kept either for 4 hours or overnight at 4C 
to restore the integrity of the cell membrane to ensure that cells were healthy prior to 
further treatments. Enriched RGCs were re-suspended in PBS at a concentration of 
5x106 cells/mL and labeled with 1 μM CFSE in PBS/1% FBS for 5 min at 37°C (146). 
Cells were quenched three times for 10 minutes on ice bucket in 20 mL volume with cold 
media-containing 10% serum. Labeled enriched RGCs (1x105 per well) were cultured in 
96-well bottom plates for 48 hours at 37°C. At 0 and 48 hours, cells were harvested, 
washed and analyzed. Acquisition proceeded using a BD LSRII Flow Cytometer 
equipped with 4-lasers (BD Biosciences, San Jose) and analyses were performed using 
FlowJo software (Tree Star, Inc., Ashland, OR), Cell Proliferation application. A 
reduction in median fluorescent intensity (MFI) is indicative of mitotic activity. 
 
 
RGC culture 
 
 The culture conditions developed Alissa Winzeler and Jack T. Wang (147) was 
followed for the maintenance of sorted mouse RGCs in monolayer culture in a 96 well 
plate. The cells were cultured in absence of serum, as the factors in serum are not well 
defined and can vary widely between sample batches. Also, presence of serum in culture 
has the potential to alter cellular responses dramatically. The medium contained 
Dulbecco's modified Eagle's medium, Neurobasal medium, plus insulin (5g/mL), 
progesterone sodium pyruvate (110 g/mL), penicillin (100U/mL), streptomycin 
(100U/mL), thyroxine (T3; 40 ng/mL), L-glutamine (292 g/mL), NS21 supplement 
(1X), N-acetyl-L-cysteine (NAC; 5 g/mL). Additional serum-free supplements were 
added to further promote optimal RGC survival, this included Bottenstein-Sato 
supplement (SATO; 1X). SATO was prepared by combining BSA (10mg/mL), 
transferrin (10mg/mL), putrescine (1.6mg/mL), progesterone (6 g/mL), sodium selenite 
(4g/mL). Additional trophic factors were also added to promote RGC health and 
survival, these include- brain derived growth factor (BDNF; 50 g/mL), ciliary 
neurotrophic factor (CNTF; 10 g/mL) and forskolin (4.2 mg/mL). Seeding densities 
ranged from 40,000-60,000 cells/well. Cultures were incubated at 37°C in a humidified 
atmosphere containing 10% CO2 and 90% air. 
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siRNA transfection in primary RGCs 
 
 Mitotically active RGCs were cultured in 96 well plates for 24 hrs in RGC culture 
media (147) after which the media was replaced with Accell delivery media (Dharmacon) 
containing SMARTpool siRNA targeting mouse Pfdn2, a pool  of 4 different siRNAs 
targeting the gene to increase the potency (Target sequence 1: 
GCAAAGAACUGAACGAAUU, Target sequence 2: UGAUUAAAUGUUUUGGUCA, 
Target sequence 3: GAUUCCCACUUGUAAUUUC, Target sequence 4: 
GGACUGUCAAAGAAGUGCU; Cat no: E-062703-00-0005; Dharmacon) or a non-
targeting GFP fluorescent siRNA (Cat no: D-001950-01-05; Dharmacon) at a final 
concentration of 1 μM according to the manufacturer’s protocol. Transfected cells were 
cultured at 37°C for 48 hrs. Assessment of live cells after siRNA transfection was 
performed by labeling cells with a 1:100 solution of an amine-reactive dye, Zombie 
Red (BioLegend) diluted in PBS to avoid spectral overlap with GFP (emission: 
emission 624 nm). Cells were incubated for 20 minutes at RT followed by two washes. 
Finally, cells were suspended in PBS/1%FBS prior to analysis. 
 
 
RNA isolation, cDNA synthesis and quantitative polymerase chain reaction 
 
RNA isolation 
 
 RNA from 1.0 x 106 retinae cells was extracted using the Qiagen® miRNeasy 
Mini Kit (Qiagen, Valencia, CA) per manufacturer’s protocol. Briefly, cells were lysed 
by using a pipette, prior addition of chloroform and a series of alcohol induced 
precipitation. The extract was passed through a spin column followed by on-column 
DNase digestion to increase purity and yield. RNA purity and concentration was assessed 
by analysis on NanoDrop Spectrophotometer. RNA used for cDNA synthesis met the 
following requirements: A260:A230 ratio greater than 1.7; A260:A280 ratio between 1.8 
to 2.1. 
 
cDNA synthesis 
 
 Genomic DNA elimination and First-Strand cDNA synthesis were performed 
using SuperScript® VILO™ cDNA Synthesis Kit (Life Technologies). Briefly, 70 ng of 
RNA were combined with VILO™ Reaction Mix and Enzyme Mix using the following 
conditions: 25C for 10 minutes, 42C for 60 min and 85C for 5 minutes. For pre-
amplification of cDNA, the RT product was pre-amplified for Sncg and Pfdn2 genes 
using TaqMan® Gene Expression Assays and TaqMan® PreAmp Master Mix as per 
manufacturer’s protocols (Life Technologies Inc., Applied Biosystems). The pre-
amplified cDNA was diluted with 1x TE (Tris/EDTA) at a 1:5 ratios and 2.5 μl of the 
cDNA was used in each well for qRT-PCR reactions. 
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qRT-PCR reaction 
 
 The following amplicons were used for the qRT-PCR reaction: Sncg, 
Mm00488345_m1; Pfdn2, Mm00448103_m1; and Gapdh, Mm99999915_g1 (Life 
Technologies). The ready-to-use TaqMan® Universal Master Mix II with UNG (Applied 
Biosystems) contained AmpliTaq Gold® DNA Polymerase, dNTPs , ROX™ Passive 
Reference, optimized buffer components. Reactions were run on a Roche LightCycler® 
480 Real-Time PCR system (Roche, Indianapolis, IN) in 96-well plate format with a 10 
μL final reaction volume at Molecular Resource Center at UTHSC. All reactions were 
performed in triplicates from three independent biological replicates. Relative 
quantitation was performed using the comparative threshold (CT) after determining the 
values of CT for the reference gene Gapdh and the target gene Sncg or Pfdn2 in each 
sample. Rqwas calculated using Equation 3.1: 
 
   Rq= 2
−ΔΔC
T                                                 (Eq. 3.1) 
 
ΔCT= (CT target gene) – (CT reference gene) 
ΔΔCT = (ΔCT treatment sample) – (ΔCT reference control sample) 
 
 
Statistics 
 
 Data presented as mean ± SEM. One-way ANOVA with Tukey’s post hoc tests 
(PRISM GraphPad) were used to determine statistical significance. Differences were 
considered significant at p < 0.001. 
 
 
Correlation comparison and gene ontology tree machine construction 
 
 A secondary goal of our investigation was to identify genes that were co-regulated 
with Sncg and Pfdn2 and shared a functional relationship. As a first step in this process, 
the transcript levels of our genes of interestSncg and Pfdn2were compared using 
Pearson correlation with all 45,281 probe sets present on the Illumina V6.2 array. The top 
500 genetically correlated genes in the retinal database were selected. To produce a set of 
shared correlated transcripts, we selected all common transcripts of Sncg and Pfdn2 
within the list of the top 500 correlates of both genes. After removing the transcripts with 
genes with expression levels less than 7 based on the expression data normalization 
process. The remaining list of 163 common correlates were analyzed by Gene Ontology 
enrichment analysis WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt), as described 
previously (69, 82). GO enrichment analysis allows users to input lists of highly 
correlated genes through the web interface, identifies GO terms that are significantly 
associated with the input gene lists, and visualizes the enriched GO terms in a directed 
acyclic graph (DAG). 
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Results 
 
 
Identification of Pfdn2 as a candidate gene modulating Sncg expression in murine 
RGCs 
 
 To identify the genomic regions that modulate Sncg expression in the retina, we 
used a systems genetics approach using the Illumina Array data from murine retinae. On 
the Illumina arrays, Sncg is represented by two probe setsILMN_2939277 and 
ILMN_2598478that hybridize to nucleotides within exon 4 and 1, respectively. Both 
probe sets map with significant likelihood ratio statistic (LRS) scores to the same location 
on the minus strand on Chr 14 at 35.187676 Mb. Because the ILMN_2598478 probe set 
reflected higher average expression levels, it was selected to represent Sncg in our 
analyses. The expression of Sncg in the retina among BXD mice varied (Figure 3-2) with 
BXD15 having the lowest Sncg gene expression of 12.650.03 (expression Log2  SEM) 
and BXD61 having the highest at 14.470.10. The average expression among all BXDs 
was 13.800.33. The parental lines, C57BL/6J and DBA/2J, had Sncg expression levels 
of 13.750.15 and 14.270.09, respectively at 1-2 months of age (Figure 3-2; Appendix 
B, Table B-1). The heritability of the variation in Sncg expression was 0.57. This result 
demonstrates that 57% of the variation in Sncg expression was due to genetic effects; and 
the remaining 43% was due to environmental influences. The six SNPs and two deletions 
in Sncg (Table 3-1) likely contribute to the genetic component of the heritability. The 
simple interval map shows a significant trans-eQTL for Sncg on distal chromosome 1 
(Figure 3-3). The maximum LRS score of the locus was 34.1 Mb, which is equivalent to 
a LOD ratio of 7.40. The confidence interval of this strong QTL extends from 171.5 to 
183.5 Mb (Figure 3-3 inset). 
 
 To identify the candidate gene(s) that modulates the expression of Sncg in the 
retina, we performed partial correlation analysis within GeneNetwork (Figure 3-4). A 
partial correlation reflects the level of association between a primary variable (i.e., Sncg 
expression level) and a target variable (i.e., upstream regulator of Sncg expression level) 
after controlling for one or more variables (i.e., the genetic variability of the trans-eQTL 
peak on Chr 1 (120). In our study, applying partial correlation analysis allowed us to 
mathematically control for the LRS peak on Chr1 and identified a single gene candidate, 
Pfdn2 (partial Pearson correlation value: r=0.656; p=3.73x10-13). No other genes in that 
interval had significant expression levels and significant correlation values. This outcome 
solidified Pfdn2 as the candidate upstream modulator of Sncg. On the Illumina array, 
Pfdn2 is represented by one probe setILMN_129667that hybridizes to exon 4 (Chr1 
at 173.286888 Mb on the plus strand). The expression level of Pfdn2 varied among the 
BXD strains from a low of 12.490.10 in BXD13 to a high of 14.410.2 in BXD39, with 
an average expression of 13.450.08 (Figure 3-5).  The parental lines, C57BL/6J and 
DBA/2J, had Pfdn2 expression levels of 13.630.21 and 13.840.23, respectively at 1-2 
months of age (Appendix B, Table B-2). The heritability of the variation in Pfdn2 
expression was 39% and the remaining 61% of the variation in the expression was due to 
environmental influences. To determine if there was any association between Sncg and 
Pfdn2 in healthy young adult mice eyes to performed Pearson correlation analysis. The 
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Figure 3-2. mRNA expression levels of Sncg across BXD strains and parental strains 
 
Rank-ordered mean Sncg mRNA levels across the BXD recombinant inbred family. The expression of Sncg in the retina among BXD 
mice varied with BXD15 having the lowest Sncg gene expression of 12.650.03 (expression Log2  SEM) and BXD61 having the 
highest at 14.470.10. The BXD strains and parental strains are depicted in grey and black, respectively. Values denote normalized 
relative mRNA expression levels on Log2 scale (meanSEM). 
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Table 3-1. Summary of candidate genes Sncg and Pfdn2 
 
Gene 
I.D. 
Location Max LRS Value  
and  
Location 
Probe set I.D. and 
BLAT Specificity 
Markers 
Flanking 
the Gene 
Mean 
Expression 
Level 
SNPs and Indels 
Sncg Chr 14 @  
35.187676 Mb  
34.3; 
Chr1:174.792334 
ILMN_2598478 
;2.5 
rs13482135@ 
36.200742 Mb 
13.804  Six intronic SNPs 
 Two deletions 
        
Pfdn2 Chr 1 @  
173.286888 Mb 
12.8; 
Chr5:85.890222 
ILMN_1219667 
;3.1 
rs3722740 @ 
173.679247 Mb 
12.8  48 intronic SNPs 
 One 3’UTR SNP 
 One synonymous SNP 
in exon 4 
(A→ A, gcA →gcG) 
 Four insertions 
 Six deletions 
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Figure 3-3. QTL mapping of Sncg 
 
A significant trans-eQTL for Sncg is present on chromosome 1 at 167-190 Mb. Red and gray horizontal lines dictate significant and 
suggestive thresholds, respectively. The purple triangle indicates the location of Sncg within the genome. The insert depicts a zoomed-
in view of the trans-eQTL on Chr1, which shows the location of Pfdn2 within the LRS peak. 
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Figure 3-4. Partial correlation analysis 
 
The screen shot depicts the partial correlation analysis using the tools available on GN. Select and add Sncg into the BXD Trait 
Collection in addition to two SNP markers rs8242766 and rs4136041, which are located at the borders of the QTL on Chr 1 between 
172 and 178Mb (the location of the trans-eQTLs). 
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Figure 3-5. Expression levels of Pfdn2 across BXD strains and parental strains 
 
Rank-ordered mean Pfdn2 expression levels across the BXD family of mice. The expression level of Pfdn2 varied among the BXD 
strains from a low of 12.490.10 in BXD13 to a high of 14.410.2 in BXD39, with an average expression of 13.450.08. The BXD 
strains and parental strains are depicted in grey and black, respectively. Values denote normalized relative mRNA expression levels on 
Log2 scale (meanSEM). 
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expression levels of Sncg and Pfdn2 in the retinae of BXD mice aged 1-2 months were 
positively correlated (Pearson correlation value: r=0.609; p=3.38x10-09; Figure 3-6A), 
which demonstrates that the two genes co-vary in the healthy retina. 
 
 As DBA/2J mice age, retinal ganglion loss becomes prominent. To investigate the 
relationship between Sncg and Pfdn2 in aged DBA/2J mice, we used a GEO dataset 
generated by Howell et al. (38). As noted by the authors, their DBA/2J mouse panel 
exhibited varying degrees of glaucoma-associated damage at 10.5 months including an 
increase in IOP and optic nerve head damage. On the Affymetrix panel used by Howell et 
al., Sncg is represented by one probe set, 1417788_at, which hybridizes to exon 1 of Sncg 
(Chr 14 at 35.183635 on the minus strand). On the same Affymetrix array, Pfdn2 is 
represented by two probe sets, 1421950_at and 1435620_at, which hybridize to the last 
three exons and far 3’UTR, respectively. Because probe set 1421950_at hybridizes to 
exons rather than a regulatory region, it was used as the single representation of Pfdn2 
expression in our studies. The average expression levels of Sncg and Pfdn2 across the 
glaucomatous DBA/2J mice were 10.000.85 and 11.000.22, respectively. A significant 
variation in the expression of Sncg was noted among these mice, which ranged between a 
low of 8.08 in a mouse with a high degree of glaucomatous damage and a high of 10.72 
in a mouse with a low degree of optic nerve damage. Pdfn2 expression varied in an 
inverse manner with an expression of 10.62 in a mouse with a low degree of 
glaucomatous damage to 11.54 in a mouse with a high degree of glaucomatous damage. 
The direct Pearson correlation between Sncg and Pfdn2 across the D2 panel was 
significant (r=-0.819; p=1.09x10-14; Figure 3-6B). 
 
 
Subcellular localization of SNCG and PFDN2 demonstrate cytosolic co-localization 
in mouse and human RGCs 
 
 To compile additional evidence to support our hypothesis that Pfdn2 modulates 
Sncg expression, we determined the subcellular localization of both proteins in retinae 
from healthy mouse eyes using immunohistochemical analyses (Figure 3-7). SNCG was 
strongly detected in GCL in the retinas of 3 month old mice indicating that SNCG 
expression is limited to cells in the GCL (Figure 3-7A, B and C). PFDN2 
immunofluorescence was ubiquitous in retina was deteched in NFL, GCL, IPL, OPL and 
ONL (Figure 3-7D, E and F). The negative controls using only secondary antibody for 
both SNCG and PFDN2 are shown in Figure 2G-I and 2J-L, we observed no cross 
reactivity with specific antibodies used in this study. In these investigations, identical 
procedures including confocal laser settings were maintained throughout to allow for 
qualitative comparisons between samples. Cross sections of healthy retinae from both 
mice (Figure 3-8A, B, C and D) and human (Figure 3-8I, J, K and L) illustrate co-
localization of SNCG (red) and PFDN2 (green) in the cytoplasm of RGCs and also in the 
NFL. In contrast, the sub-cellular localization and abundance of SNCG in retinae of 
glaucomatous BXD66 mice was decreased compared to healthy mice (Figure 3-8E, F, G 
and H). Similarly, there was an identical reduction in the intensity of SNCG labeling in 
the retina from a human glaucoma patient (Figure 3-8M, N, O and P) compared to a 
healthy control (Figure 3-8I, J, K and L). Changes were specific to SNCG   
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Figure 3-6. Pearson correlation between Sncg and Pfdn2 expression in retinas of 
BXD mice 
 
(A) The graph represents a strong positive correlation between expression levels of Sncg 
and Pfdn2 (p=3.37x10-09) in the retina of young mice with no glaucomatous damage. 
Numbers indicate BXD strains, and the parents. (B) The graph represents a strong 
negative correlation between Sncg and Pfdn2 (p<10-14) is present in retinae from aged 
DBA/2J glaucoma mice. Optic nerves from aged DBA/2J mice derived from the Howell 
et al, data set had the following degrees of axonal damage: Severe (greater than 50% 
axons lost, Δ); Moderate (10%–50% of axons lost, Θ); No/early 1 (no detectable damage, 
); No/early 2 (no detectable damage, ); and Control (no glaucoma; 10.5-month-old 
DBA/2J-Gpnmb+/Sj mice, ).  
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Figure 3-7. Detection of SNCG and PFDN2 in healthy mouse retina 
 
(A-C) In healthy control mouse SNCG (green) immunoreactivity was detected in the 
GCL. (D-F) PFDN2 (green) was ubiquitously expressed in all the retinal cells. To-PRO-
III iodide (blue) counterstained the nuclei. Merged images are shown in A and D. (G-I 
and J-L) Negative controls show no non-specific labeling of the antibodies. NFL= nerve 
fiber layer, GCL=ganglion cell layer, IPL=inner plexiform layer, INL=inner nuclear 
layer, OPL=outer plexiform layer, ONL=outer nuclear layer. Scale bars: 10µm. 
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Figure 3-8. Co-localization of SNCG and PFDN2 in healthy and diseased mouse 
and human RGCs 
 
(A-D) In a control mouse (C57BL/6) and (E-H) a mouse model of glaucoma (BXD66), 
SNCG (red) was localized throughout the cytoplasm, nuclei and nerve fiber layer. 
PFDN2 (green) was localized to RGC cytoplasm and the nerve fiver layer. To-PRO-III 
iodide (blue) counterstained the nuclei. Merged images are shown in A and E. In a human 
donor eye with no diagnosis of disease (I-L) and a donor with glaucoma (M-P), SNCG 
localization patterns and relative levels were identical to those found in mice. Merged 
images are shown in I and M. Arrows in E and M mark reduced expression of SNCG in 
the glaucomatous retina. GCL=ganglion cell layer, NFL=nerve fiber layer. Scale bars: 
10µm. 
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immunoreactivity (Figure 6B, 6F, 6J, 6N), as we did not observe changes in PFDN2 
levels between healthy and diseased retinae (Figure 3-8C, G, K and O). These data 
demonstrate that SNCG expression is limited to RGCs, which corroborates with 
previously published studies in RGCs, yet PFDN2 is expressed in RGCs as well as other 
cells throughout the retina. 
 
 
Quantitative and qualitative analyses of SNCG and PFDN2 in isolated RGCs 
 
 Using dissociated retinal cells and flow cytometry, we provide additional 
evidence to support our hypothesis that both SNCG and PFDN2 are co-expressed in 
RGCs. Each dissociated mouse retina yielded on average 5X1061.2 cells based on 
trypan blue exclusion. Flow cytometry analyses revealed that we consistently obtained 
greater than 952.4% live cells (Figure 3-9). Downstream analyses were performed 
exclusively on live cells. To investigate the percentage of retinal cells that expressed both 
PFDN2 and SNCG, we used intracellular labeling. Figure 3-10 (left panel) shows that 
only a small percentage (<2%) of live retinal cells are SNCG+. We expected that the 
percentage would be small considering SNCG is expressed solely by RGCs which 
comprise ~0.5% of all retinal cells (148). In contrast, all live murine retinal cells were 
positive for PFDN2, a ubiquitously expressed chaperone protein (Figure 3-10 middle 
panel). Among experiments, we measured an average of 1000 and 1.50.4% of total 
retinal cells that express PFDN2 and SNCG, respectively. Retinal cells probed 
simultaneously with antibodies for both proteins showed that <2% of live retinal cells 
have the PFDN2+SNCG+ phenotype (Figure 3-10, right panel).  
 
 Intracellular labeling using anti-SNCG and anti-PFDN2 antibodies allow for 
robust identification of RGCs, but it renders them unviable for downstream investigations 
because the cells are fixed and permeabilized as they become metabolically inactive. To 
overcome this shortcoming, we isolated primary RGCs using FACS and cell surface 
antibodies. As shown in Figure 3-11, we performed a positive selection using a Thy1+ 
(Pan-Thy1) antibody and a negative selection using a CD48 antibody to remove 
monocytes, macrophages and microglia. To verify that the live Pan-Thy1+CD48neg cells 
were RGCs, we performed intracellular labeling on a small aliquot, as detailed above. 
Among the live retinal cells, 602.1% were Pan-Thy1+ (Figure 3-11, left panel) and 
233.6% of them were CD48+ (Figure 3-11, middle panel). This positive and negative 
selection strategy allowed us to enrich for RGC with a Live Pan-Thy1+CD48neg 
phenotype. We further verified this phenotype using the SNCG intracellular marker and 
demonstrate that 453.5% of enriched cells are immunopositive for SNCG. This 
indicates that our enrichment strategy increases the number of RGCs 30-fold (45± 3.5% 
vs 15±0.4%) compared to the number found within the retina (Figure 3-11, right panel). 
 
 Enriched RGCs with a Live PanThy1+CD48neg phenotype were maintained in 
RGC media at 4°C overnight after sorting to allow for restoration of the plasma 
membrane. We then labeled cells with 1 M CFSE to determine cellular proliferation and 
quantified CFSE fluorescence over time to determine cell viability and proliferative 
status so they could be used in downstream testing (Figure 3-12). Flow cytometry   
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Figure 3-9. Dissociated retinal cells were labeled with Zombie Aqua™ for 
live/dead cell analysis 
 
Top Panel, representative pseudocolor plot showing Zombie Aqua+ cells, which depicts 
dead cells. Bottom Panel, in our cell suspension approximately 97.5% of cells are alive, 
based on exclusion of Zombie Aqua™ dye.  
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Figure 3-10. Histogram analysis showing the percentage of retinal cells labeled 
with anti-SNCG anti-PFDN2 antibodies 
 
Pseudocolor plot shows <2% of retinal cells are positive for both SNCG and PFDN2. 
 
 
 
 
 
 
Figure 3-11. Cell enrichment strategy 
 
Cells were positively selected based on Pan-Thy1 (Thy1.1 and Thy1.2 antibodies) 
staining. The Pan-Thy1+ population was negatively selected for CD48 to have a final 
phenotype of Live Pan-Thy1+CD48neg cells. An aliquot of the sorted cells was evaluated 
for intracellular SNCG labeling, which exhibit 41% positivity. 
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Figure 3-12. Cellular proliferation was measured by CFSE labeling 
 
Distribution shift indicate that sorted Pan Thy+CD48neg cells undergo cell division.  
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analysis revealed that RGCs were alive and underwent mitotic division (Figure 3-12), 
thus making them competent for mechanistic studies.  
 
 
siRNA mediated knockdown of Pfdn2 significantly reduced the expression of Sncg 
in enriched RGCs 
 
 To investigate whether the enriched RGCs are suitable for siRNA transfection, 
cell survival was measured by using Zombie Aqua™ viability dye (BioLegend, San 
Diego, CA) after siRNA transfection. No significant difference (p>0.05) in viability was 
observed between the mock-transfected cells and those transfected with control siRNA or 
Pfdn2 siRNA (Figure 3-13A). To directly investigate if Pfdn2 modulates Sncg 
expression in enriched RGCs, the levels of Pfdn2 and Sncg mRNA transcripts were 
measured 48hours after transfecting the cells with Pfdn2 siRNA. Quantitative 
transcriptional analyses demonstrate that both Sncg and Pfdn2 are expressed in enriched 
primary RGCs (Figure 3-13B). A significant knockdown of Pfdn2 expression (61% 
reduction; p≤0.001) was observed in the cells transfected by Pfdn2 siRNA compared to 
cells exposed to control siRNA. Furthermore, knockdown of Pfdn2 expression using 
siRNA resulted in a significant reduction in the expression of Sncg mRNA compared to 
samples treated with control siRNA (57% reduction; p≤0.001) and samples without any 
siRNA treatment (89% reduction; p≤0.001) (Figure 3-13B), demonstrating that 
decreasing Pfdn2 expression levels caused a significant reduction in Sncg expression in 
primary enriched murine RGCs. These results strongly suggest that Pfdn2 modulates 
Sncg in RGCs. 
 
 The transcriptional downregulation of Pfdn2 reduced PFDN2 and SNCG proteins 
coded by Pfdn2 and Sncg, respectively. Flow cytometry analyses (Figure 3-13C) after 
cell transfection resulted in a significant reduction in the number of PFDN2+ cells 
(18.8±8.2% when transfected with Pfdn2 siRNA compared to 39.1±3.8% when 
transfected with Control siRNA, p=0.049). Under this same experimental condition, we 
also found a statistically significant reduction in the percentage of enriched RGCs that 
were immunopositive for SNCG (10.2±10.1% when transfected with Pfdn2 siRNA 
compared to 41.7±0.6% when transfected with Control siRNA, p=0.047). Collectively, 
our results show that knockdown of Pfdn2 using siRNA results in a decrease in both the 
amount of Sncg transcript and the number of SNCG+ cells. 
 
 
Network enrichment highlights the involvement of mitochondrial function 
 
 As a next step in our investigation, we identified the top 500 genes with variation 
in expressions levels that were correlated with changes in Sncg or Pdfn2 expression 
levels. The comparison of shared correlates of Sncg and Pfdn2 generated a list of 163 
genes (Figure 3-14). This list was submitted for GO tree enrichment analysis and a 
directed acyclic graph was generated that grouped the transcripts according to molecular 
function. Ten of 32 (31%) categories in the graph were statistically over-represented in 
the GO tree generated from the 163 shared correlates. Five out of eight (62%) clusters 
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Figure 3-13. Pfdn2 knockdown inhibits Sncg expression in enriched primary RGCs 
 
(A) Viability of retinal cells defined by Zombie Aqua™ after control siRNA and Pfdn2 siRNA transfection for 48 hours is similar to 
untreated cells (p>0.05). (B) Transcriptional analyses for Sncg and Pfdn2 in primary mouse RGCs demonstrate a significant 
downregulation of Sncg mRNA after Pfdn2 siRNA treatment (*p<0.001). There is a significant difference between the level of Pfdn2 
expression in the control siRNA treatment group and the Pfdn2 siRNA treatment group (# p<0.001). There is also a significant 
difference between the level of Sncg expression in the control siRNA treatment group and the Pfdn2 siRNA treatment group (* 
p<0.001). Results are presented as a fold change after normalizing to the level of Gapdh mRNA. (C) Protein analyses by flow 
cytometry show a significant reduction in the percentage of enriched RGCs that were immunopositive for SNCG and PFDN2 after 
Pfdn2 siRNA treatment. There is a significant difference between the number of cells that are immunopositive for PFDN2 (# p<0.05) 
and SNCG (* p<0.05) after transfection with Pfdn2 siRNA. Specific isotype controls were used to distinguish between positive and 
false positive cells. Results are shown as means ± SEM from three independent biological replicates performed in triplicate. 
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Figure 3-14. Venn diagram summarizing number of gene transcripts with 
expression levels that are correlated with Sncg and Pfdn2 expression levels, along 
with the number of shared correlates between the two groups 
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contained genes related to mitochondrial function: “Oxidoreductase activity” (11 genes); 
“Hydrogen ion transmembrane transporter activity” (4 genes); and “Structural constituent 
of ribosome” (4 genes); “NADH dehydrogenase activity” (2 genes); and “Cytochrome-c 
oxidase activity” (2 genes) (Figure 3-15; Appendix B, Table B-3 to B-7). The gene 
products encoded by these transcripts are present in mitochondria, and are involved in 
maintaining the potential difference across the inner mitochondrial membrane 
maintaining normal physiological function (Figure 3-16) (149-169). 
 
 
Discussion 
 
 In this investigation, we have combined cutting edge methodologies of systems 
genetics, bidirectional studies using multiple species, meta-analyses, 
immunohistochemistry, FACS sorting and gene knockdown studies to identify and 
validate the identity of a genetic modulator of Sncg, a gene that has been previously 
implicated in RGC death in glaucoma. Our investigation identified Pdfn2 as an upstream 
regulator of Sncg in RGCs. In healthy retinae, the protein levels of both genes are 
significantly correlated in a positive manner. In addition, they are co-localized in the 
cytoplasm of RGCs and in the nerve fiber layer. Targeted downregulation of Pdfn2 in an 
enriched population of murine RGCs resulted in both the suppression of Sncg mRNA and 
also in the number of enriched RGCs that express SNCG. We have further demonstrated 
using two mouse glaucoma models–BXD66 and DBA/2J, and the retina from a human 
donor glaucoma patient, that the relationship between the two genes is modified in the 
diseased state. Specifically, in glaucoma, the relationship between the genes appears to 
have changed to an inverse relationship with reduced Sncg levels as the disease 
progressed. SNCG protein levels also dropped to nearly negligible levels in RGCs from 
subjects with advanced disease, while PDFN2 levels have remained steady.  
 
 Previously, linkage analyses and clustering methods have been used to identify 
candidate genes, such as complement component 1a (C1qa), that were associated with 
glaucoma in BXD strains (170). In our investigation, we went a step farther and 
utilized partial correlation analysis to solidify the relationship between Sncg and Pfdn2 in 
the mouse retina. The statistically significant partial correlation between Sncg and Pfdn2 
reflects gene–gene interactions, as well as a regulatory relationship between the genes. 
The partial correlation approach has successfully been developed and applied to 
transcription data from yeast (171), Arabidopsis thaliana (172 ), HeLa cells (173), and 
breast cancer tumors (174). To our knowledge, it has not previously been used to study 
the interactions between two genes in the mouse retina.  
 
 Sncg has been suggested to be a marker for glaucoma due to the association 
between RGC degeneration and the loss of Sncg mRNA and protein expression in both 
human glaucoma patients and animal models of glaucoma (139, 142, 143). In 
neuroretinal cells, SNCG plays an essential regulatory role in resistance to stress, and 
neuroprotection (175 ). Another report demonstrated that a reduction in SNCG protein 
levels initiates an apoptotic death cascade due to the dephosphorylation of BCL2-binding 
protein (176). In addition, the loss of Sncg correlates with increased RGC death as shown   
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Figure 3-15. Gene ontology analysis of the shared correlates of Sncg and Pfdn2 are 
presented 
 
Categories that are statistically over-represented are presented (adjusted p=5.9x10-2 for 
all groups). Categories indicated with a red bar indicate mitochondria-associated genes 
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Figure 3-16. Gene ontology analysis of the shared correlates of Sncg and Pfdn2 
 
Categories that are statistically over-represented are presented in (adjusted p=5.9x10-2 for 
all groups). Categories indicated with a red boxes indicate mitochondria-associated genes. 
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in DBA/2J mice (143). Apart from its neuroprotective role, SNCG acts as a molecular 
chaperone (177) by interacting with myocilin, a glycoprotein that when mutated is 
associated with glaucoma (178). Collectively, the literature suggests that SNCG plays a 
critical role in RGC health, yet the regulation of this gene had not yet been previously 
investigated. 
 
 PFDN2 is a ubiquitously expressed protein in the retina as a heterohexameric co-
chaperone that in eukaryotes and it is also a component of the prefoldin complex (179). 
Of direct relevance to our investigation, prefoldins 1-6 are neuroprotective and they 
specifically prevent the aggregation of misfolded proteins, such as αsynuclein (180, 
181). When mutated, Pfdn2 is likely involved in the formation of toxic β-amyloid 
oligomers that are a common pathology of multiple neurodegenerative diseases (182) In 
addition, Lee et al., have reported that Pfdn5 is crucial for normal sensory and neuronal 
development (183). Mutations in other family members, such as Pfdn3, cause structural 
disorganization of neuronal microtubules and microfilaments (184). Several lines of 
evidence suggest that the main cytoskeletal proteins, including microtubule-associated 
proteins and neurofilaments, are not normally transported along the ocular axon stump of 
degenerated RGCs, which leads to apoptosis (185). Strong immunolabeling of SNCG and 
PFDN2 in the nerve fiber layer of both mouse and human retinae in our study suggests a 
possible role of these genes in microtubule regulation or trafficking in axons of RGCs. 
 
 Pfdn2 is located in the QTL rich region (Qrr1) on Chr 1, which is a genomic 
region of unusually high gene density and contains major regulatory QTLs for various 
behavioral, metabolic, physiologic and immunological processes (179, 186, 187) 
including diverse epileptic traits (188 ). The distal portion of Qrr1 is strongly implicated 
in modulating RNA metabolism, translation, tRNA aminoacylation, and transportation of 
transcripts into neuronal dendrites (186). Qrr1 also modulates behavioral alterations in 
respect to activity and anxiety (189, 190). Physiologically relevant genes such as formin-
2 (Fmn2), regulator of G-protein signaling 7 (Rgs7) and a cluster of tRNAs are 
modulated by the Qrr1 distal region. However, none of these genes had significant partial 
correlation values with Sncg and therefore they were excluded from the list of candidate 
upstream modulators of this Sncg. 
 
 In glaucomatous DBA/2J mice, we identified an inverse relationship between 
Sncg and Pfdn2. Specifically, mice that have the highest degree of degeneration have the 
lowest Sncg level, yet the highest level of Pdfn2 expression. Using both qualitative and 
quantitative methods, we demonstrate that in compared to healthy individuals with no 
disease, SNCG is reduced in the retina of glaucoma patients. These findings are shared by 
both humans with a diagnosis of glaucoma and a novel BXD model of glaucoma. It is 
plausible that in glaucoma that RGCs upregulate Pdfn2 in an attempt to increase Sncg 
expression. Its known that glaucoma induces stress to the RGCs, which leads to damage 
to proteins in the cells. Stress induced synthesis of chaperones is impaired in in diseases 
such as glaucoma. It is plausible that reduction in Sncg expression in aging DBA/2J is an 
effect of age-related changes associated with glaucoma, to protect the cells from damage 
Pfdn2 expression upregulates to compensate for the loss of chaperone function in RGC. 
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 Due to the complex cellular heterogeneity of the retina, it is relatively difficult to 
reliably obtain a pure RGC population from retina. In particular, the comparative analysis 
of molecular regulation or profiles is hampered by the lack of an adequate methodology 
for the selective purification of RGCs from retinae. I have addressed this caveat in 
Chapter 4 of this dissertation. A representative histogram shows that using our 
enrichment protocol 41% of the sorted live enriched RGCs were SNCG-positive. 
Moreover, our CFSE results indicate that these cells are viable and are capable of 
dividing for at least 48hrs under specific cell culture conditions. We have also been 
successful in keeping enriched RGCs alive for upto 6 days. The cell culture conditions 
that we used does not include serum. Presence of serum in culture has the potential to 
alter cellular responses dramatically. Serum-free media has proven to be critical both in 
addressing how RGCs behave independently of other signals and in identifying the 
molecular signals that mediate specific neuronal–glial interactions in the CNS (191-195). 
Addition of trophic factors such as BDNF, CNTF, and insulin which are usually made by 
cells in contact with RGCs promote RGC health and survival. The present strategy allows 
for the enrichment population of murine RGCs that retain the integrity of their proteins, 
DNA and RNA for subsequent downstream biochemical and molecular analyses. 
 
 Using our enriched primary RGCs, we used a siRNA-based approach to 
knockdown Pfdn2 gene expression and measure the effect upon Sncg expression. Our 
data show that targeted siRNA successfully downregulated Pfdn2 by ∼61% p≤0.001 at 
48 hour post transfection. Comparative gene expression analyses revealed an equally 
effective downregulation of Sncg in enriched RGCs treated with Pfdn2- targeted siRNA. 
Our data demonstrate that, Pfdn2 is upstream of Sncg and it directly modulates Sncg 
expression in enriched mouse RGCs. The majority of the biological process categories 
represented in the GO enrichment analysis from Sncg and Pfdn2 shared correlates are 
associated with mitochondrial structure and function. RGCs are responsible for 
transmitting visual information from the retina to the lateral geniculate nucleus. Due to 
this large anatomical distance, RGCs must transport metabolites and organelles via 
axonal transport, a process with a high-energy demand. Mitochondria play a key role in 
the life and death of neurons. Any dysfunction of axonal transport or mitochondrial 
function can have severe consequences on RGC function and viability (196, 197). 
Additional studies show that mitochondria are a direct target of α-synuclein in 
Parkinson’s disease (198), which lends support for our findings. Several lines of evidence 
suggest that transport of mitochondria within a cell occurs by interactions with a variety 
of cytoskeletal proteins which contributing to maintenance cellular physiology (199, 
200). 
 
 In summary, our results show that genetic mapping and network modeling can be 
combined with multiparametric flow cytometry and gene silencing to identify and verify 
the genetic regulation of a retinal gene. Ours is the first investigation in which the 
relationship between Sncg and Pfdn2 has been established in both the intact retina and in 
enriched primary murine RGCs. The discovery of this relationship may help in guiding 
studies that explore the disease mechanisms associated with altered protein transport and 
folding in RGCs. In glaucoma the identification and confirmation of these two proteins in 
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RGC health and disease holds great promise for developing molecular targets to slow 
RGC damage, which in turn will preserve vision. 
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CHAPTER 4.    ISOLATION AND VALIDATION OF PRIMARY MURINE RGCS 
FROM HEALTHY AND DAMAGED RETINAE* 
 
 
Introduction 
 
 Glaucoma is a complex multifactorial disease characterized by the progressive 
dysfunction and loss of RGCs and associated visual field deficits. It remains a leading 
cause of vision loss affecting 70 million people worldwide (201). In spite of notable 
technical advances, the cellular mechanisms underlying their loss remain unclear. This is 
in part due to the lack of standardized, reliable protocols to isolate large numbers of 
highly enriched RGCs and/ or a RGC line for in vitro mechanistic studies (202, 203). 
Identifying the genetic basis or cellular mechanisms causing RGC degeneration would be 
the first step towards development of efficacious therapies to slow or reverse RGC 
damage, in turn preserving vision. The lack of a validated RGC population represents a 
large unmet need for the vision research community at large. 
 
 The isolation and enrichment of primary murine RGCs is essential for 
investigating RGC responses to specific therapies in vitro. A number of challenges have 
prevented progress towards the use of a homogeneous primary murine RGC population. 
First, a major challenge lies on the scarce number of RGCs that can be isolated from 
murine retinae (148, 204, 205). Second, current signature markers for the identification of 
RGCs are intracellular markers (206-208), impeding the isolation of viable, metabolically 
active cells downstream for in vitro studies.  Third, current protocols are lengthy and 
have not been standardized for the isolation of primary murine RGCs from dissociated 
retinae. Barres et al. (209) adapted the immunopanning technique into a two-step process 
to purify RGCs. The process includes depletion of macrophages and endothelial cells, 
followed by positive selection of cells responding to anti-Thy1. Recently, Hong (210) 
optimized a similar process that included positive selection of Thy1+ cells using magnetic 
beads followed by cell sorting. Both approaches require lengthy isolations and their 
yields are inconsistent. A commercial kit is available for isolating RGCs from retinae 
(211), however, it has two major limitations: the kit is for exclusive use in rats, yet mice 
are the primary animal model used in vision research; and the specificity of this kit for 
RGCs is debatable, as amacrine cells could also be isolated with this method. In recent 
years the use of Dynabeads or flow cytometry in conjunction with monoclonal antibodies 
(212) or lectins (213) has provided powerful tools to improve the purity of isolated cells. 
 
 Flow cytometry, also known as FACS, is a powerful method that analyzes cell 
suspensions and provides quantitative and qualitative data with a high level of sensitivity. 
FACS cellular discrimination is based on physical properties such as surface area and the 
                                                 
 
* Reprinted with permission from 2007‐2016 Frontiers Media SA. Chintalapudi SR, Djenderedjian L, 
Stiemke AB, Steinle JJ, Jablonski MM, Morales-Tirado VM. Isolation and Molecular Profiling of Primary 
Mouse Retinal Ganglion Cells: Comparison of Phenotypes from Healthy and Glaucomatous Retinas. Front 
Aging Neurosci. 2016 May 18;8:93. doi: 10.3389/fnagi.2016.00093. eCollection 2016. PubMed PMID: 
27242509; PubMed Central PMCID: PMC4870266. 
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internal complexity or granularity of the cells (214). Multi-dimensional analysis, based 
upon the expression of proteins on the cell surface as well as intracellularly, can be 
performed by the combination of antibodies tagged with fluorochromes. Current FACS-
based cell sorting techniques allow for the separation of up to four different cell 
populations based on multivariate properties. Sorted cells can be collected and are viable 
for downstream analyses. 
 
 In the present study, we developed a novel flow cytometry-based protocol to 
generate a homogeneous RGC population from murine retinae. We employed a highly 
stringent sort strategy coupled with qualitative PCR (qPCR) and intracellular staining 
with RGC-signature markers to verify the purity and homogeneity of the enriched 
population. Our isolation technique provides a powerful tool for vision research to assist 
in the understanding of the molecular pathways and key players in preservation of RGC 
function and health to develop novel therapies for vision loss (Figure 4-1). 
 
 
Methods 
 
 
Dissociation of murine retinae 
 
 Two hundred C57BL/6J mice between 5-7 weeks of age, 22 BXD66 mice ages 5 
weeks (young) and >12 months (old) were used in this study. All procedures were 
approved by the Institutional Animal Care and Use Committee (IACUC) review board at 
the University of Tennessee Health Science Center (UTHSC) and followed the 
Association for Research in Vision and Ophthalmology (ARVO) Statements for the Use 
of Animals in Ophthalmic and Vision Research, in addition to the guidelines for 
laboratory animal experiments (Institute of Laboratory Animal Resources, Public Health 
Service Policy on Humane Care and Use of Laboratory Animals). Mice were sacrificed 
by cervical dislocation followed by enucleation, as previously described in (215). Retinae 
were dissociated using enzymatic digestion. The resultant cell suspension was filtered 
using a Falcon 70m nylon strainer (BD Biosciences, San Jose, CA) followed by 
centrifugation at 1500 RPM x 5 minutes at RT. Cells were resuspended in PBS/1% FBS 
(Lonza, Walkersville, MD) and kept on ice until ready for use. 
 
 
Flow cytometry analyses 
 
Cell surface labeling 
 
 Cell viability was evaluated at the time of retinae cell dissociation. To ensure we 
obtain live cells after sorting, we labeled the cells with Zombie Aqua™ (BioLegend, San 
Diego, CA) a permeant dye to discriminate between live (negative for dye) and dead 
(positive for dye) cells. Live cells were treated with 1.0g of anti-CD16/CD32 per 
1.0x106 cells in 100L to block FcRII/III (clone 93; BioLegend), which minimizes non-
specific binding of the primary antibodies and in turn inhibits endocytosis, phagocytosis   
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Figure 4-1. Illustrated summary 
 
Loss of functional RGCs is an element of retinal degeneration that is poorly understood. 
This is in part due to the lack of a reliable and validated protocol for the isolation of 
primary RGCs. Here we optimize a feasible, reproducible, standardized flow cytometry-
based protocol for the isolation and enrichment of homogeneous RGC with the 
Thy1.2hiCD48negCD15negCD57neg surface phenotype. A three-step validation process was 
performed by: (1) genomic profiling of 25-genes associated with retinal cells; (2) 
intracellular labeling of homogeneous sorted cells for the intracellular RGC-markers 
SNCG, BRN3A, TUJ1, and RBPMS; and (3) by applying the methodology on RGC from 
a mouse model with elevated IOP and optic nerve damage. Use of primary RGC cultures 
will allow for future careful assessment of important cell specific pathways in RGC to 
provide mechanistic insights into the declining of visual acuity in aged populations and 
those suffering from retinal neurodegenerative diseases. 
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and antigen presentation due to FcR activation. The following primary antibodies were 
used to detect surface antigens by incubating the cells on ice for 30 minutes: anti-CD90.1 
PerCP-Cy5.5 (Thy1.1, clone OX-7, BioLegend, exhibits no cross-reactivity with 
CD90.2); anti-CD90.2 Alexa Fluor-700 (Thy1.2, clone 30-H12, BioLegend, exhibits no 
cross-reactivity with CD90.1); anti-CD48 PE-Cy7 (clone HM48-1, BioLegend, labels 
monocytes and microglia); anti-CD15 PE (clone MC-480, BioLegend, labels amacrine 
cells); and anti-CD57 (clone VC1.1, Sigma Aldrich, St. Louis, MO, also labels amacrine 
cells). Because the anti-CD57 antibody was unconjugated, a Brilliant violet 421-tagged 
secondary antibody (Life Technologies, Carlsbad, CA) was used to allow for sorting. 
 
Sorting strategy 
 
 Cells were enriched by fluorescent activated cell sorting (FACS) using a BD 
Biosciences FACSAria™ Cell Sorter equipped with 4-lasers (BD Biosciences, San Jose, 
CA). In this investigation, we used the 488nm blue, the 630nm red and the 405nm violet 
diode lasers.  Dissociated cells were maintained at 4°C using a temperature controlled 
sample injection and collection chamber. At the time of cell sorting, we used unlabeled 
murine retinal cells as controls and individual samples were labeled with antibodies 
specific for different retinal cell surface markers. We used AbC™ Total Antibody 
Compensation Bead Kit (Life Technologies) to prepare single color controls using the 
manufacturer's protocol. These are highly sensitive and efficient antibody capture beads 
with a broad multispecies reactivity. To determine the efficiency of the sort, we took a 
small sample of the eluted sorted sample followed by immediate FACS analysis. 
 
Intracellular labeling  
 
 Dissociated cells labeled as detailed above followed by 1hr fixation at 4°C using 
the BD Cytofix/ Cytoperm™ fixation/permeabilization solution (BD Biosciences) as in 
(216, 217). Cells were incubated for 1hr at 4°C in the following antibodies that were 
diluted in BD Perm/Wash buffer: anti-RBPMS (rabbit polyclonal IgG; Santa Cruz 
Biotechnology, Santa Cruz, CA; 1:100 dilution); anti-SNCG (rabbit polyclonal IgG; 
GeneTex, 1:100 dilution), BRN3A (goat ployclonal IgG; Santa Cruz Biotechnology; 
1:100 dilution); and anti-TUJ1 (mouse monoclonal IgG2a; Covance; 1:100 dilution). The 
appropriate Alexa Fluor 488 tagged secondary antibodies (1:200 dilution; Invitrogen) 
were used to allow for data acquisition and analysis. Cells were kept in PBS/1%FBS on 
ice until the time of analysis. Data acquisition was performed on a BD LSRII Flow 
Cytometer (BD Biosciences) and analyses were performed using FlowJo vX10.0.6 (Tree 
Star, Inc., Ashland, OR). To confirm results we performed additional data acquisition 
using the Miltenyi Biotec MACSQuant® 10 Analyzer (Myltenyi Biotec, San Diego, CA).  
 
Flow cytometry and confocal microscopy dual analysis 
 
 Labeled retinal cells were acquired based on area and aspect ratio, gating out cell 
debris and cell aggregates from the analysis using the Amnis® FlowSight® Imager (EMD 
Millipore, Amnis Division, Seattle, WA). Flow cytometry features include a violet (405 
nm, 100 mW), blue (488 nm, 60 mW), red (642 nm, 100 mW), and SSC (785 nm, 8 mW) 
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lasers. Data were analyzed in IDEAS software after compensation of single color control 
samples using a compensation matrix. Confocal images were taken at 20x. 
 
 
Gene analyses 
 
RNA isolation and cDNA synthesis and pre-amplification of cDNA template 
 
 RNA from 5.0x105 sorted Live Thy1.2+CD48negCD15negCD57neg cells was 
extracted following the Qiagen® miRNeasy Mini Kit (Qiagen, Valencia, CA) 
manufacturer’s specifications. RNA concentration was assessed using a Nanodrop 
Spectophotometer (Nanodrop, Wilmington, DE). cDNA was synthesized from RNA 
using the SuperScript® VILO™ cDNA Synthesis Kit (Life Technologies). Following the 
manufacturer’s instructions, we used 100ng of RNA for each reaction. Briefly, the pre- 
amplification reaction mixture was prepared using cDNA, TaqMan® PreAmp Master Mix 
and the pooled primer mix listed in Appendix C, Table C-1. Pre-amplification: the 
enzyme activation step was carried out at 95°C for 10 mins, followed by 14 cycles at 
95°C for 15 sec followed by 60°C for 4 mins. Subsequently, the pre-amplified cDNA was 
diluted 1:10 in TE buffer and was kept at -20°C until ready for use. The pre-amplification 
of cDNA step was crucial to increase the sensitivity of detection for downstream 
quantification using qPCR. As part of our stringent validation and confirmation 
techniques, we used a series of gene targets that are specific for different retinal cell 
populations, including a housekeeping gene (Hprt). The primers that were used for the 
pre-amplification step are listed in the Appendix C, Table C-1. 
 
qPCR analysis amplification efficiency test 
 
 We determined the primer efficiency and amplification efficiency by the absolute 
quantification method using a Roche LightCycler® 480 Instrument and Version 1.5.0 
Software (Roche, Indianapolis, IN). Pre-amplified cDNA was serially diluted to a range 
of concentration (1, 1:10, 1:100, 1:1000). This comparison ensured that the pre-
amplification process amplified genes with a wide variation of abundance. The 
comparative threshold (CT) values were plotted against the log concentration qPCR 
product and the slope was calculated. The closer the slope is to -3.33, the closer the 
amplification efficiency is to the 100% ideal, which indicates that there is a doubling of 
product per cycle. In addition, we performed linear regression analysis to show the 
correlation between gene expression measurements from our samples for the primers we 
validated, and a standard curve. In this study, we used CT values ranging from 15-30 in 
our assays. Three biological replicates were evaluated and the CT values were normalized 
to the endogenous gene (Hprt) control and compared to the CT values obtained from the 
pre-amplifed cDNA from murine, non-sorted retinal cells. 
 
qPCR reaction 
 
 For qPCR reaction we prepared a final volume of 10L PCR reaction mixture 
using TaqMan® Universal Master Mix, diluted pre-amplified cDNA, primers and 
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Nuclease Free water. Plates were analyzed on a Roche LightCycler® 480. Instrument 
conditions included first a hold step of 50°C for 2 mins followed by 95°C for 10 mins. 
Next, we performed 40 cycles of 95°C for 15 sec followed by 60° for 1 min. All 
measurements were made in replicates of 4. Relative quantification was performed using 
CT after determining the values of CT for the reference gene (housekeeping) and the 
target genes in each sample. The relative fold change (Rq) was calculated using the 
following formula: Rq= 2
−ΔC
T, where ΔCT = (CT target gene − CT reference gene). Data 
are presented as mean ± SEM. Differences between two means were assessed with 
ANOVA and Tukey’s post-hoc test (PRISM, Graph Pad, La Jolla, CA). Differences were 
considered significant at p<0.05. 
 
 
Immunohistochemistry 
 
 Murine retinal sections embedded in low melting point agarose were prepared 
following our published methods (144). Briefly, tissue sections were blocked with 10% 
goat serum and permeabilized with 2.5% Triton X-100. The following primary antibodies 
were used per manufacturers conditions: anti-RNA-Binding Protein With Multiple 
Splicing (RBPMS; rabbit polyclonal IgG, Santa Cruz Biotechnology, 1:100 dilution); 
anti- -synuclein (SNCG, rabbit polyclonal IgG, GeneTex, 1:100 dilution); anti-Brain-
Specific Homeobox/POU Domain Protein 3A (BRN3A, goat ployclonal IgG, Santa Cruz 
Biotechnology, 1:10 dilution); anti-Neuronal Class III ß-Tubulin (TUJ1, mouse 
monoclonal IgG2a, Covance, Princeton, NJ; 1:100 dilution); anti-HNK-1/N-CAM 
(CD57, Clone VC1.1, mouse monoclonal IgM, 1:10 Dilution); and CD15 (Clone:MC-
480, mouse monoclonal IgM, Biolegend, 1:25 dilution). The appropriate Alexa Fluor-
tagged secondary antibodies (Invitrogen, Waltham, MA; 1:200 dilution) and TO-PRO3 
iodide (Invitrogen; 1:4000 dilution) were used to indicate the location of the antigens of 
interest and nuclei, respectively. Sections were viewed and images were obtained using a 
Nikon C1 (Nikon, NY) confocal microscope within the Imaging Core Facility in the 
Hamilton Eye Institute. All microscope settings, including laser levels and gain, were 
held constant to allow for relative comparisons of signal intensity within and between 
experiments. 
 
 
Immunofluorescence 
 
 Live Thy1.2+CD48negCD15negCD57neg sorted cells (50,000 cells) were washed 
once with Hanks Balanced Salt Solution (HBSS) in followed by centrifugation at 1200 
RPM x 5 mins at RT. Cells were labeled with SYTO®59 (100nM) for 10 mins in a HBSS 
at 37°C followed by multiple washes with HBSS for 5 mins each. Cells were plated on a 
glass bottom microwell dish (35mm petri dish, 14mm microwell; MatTek Corporation, 
Ashland, MA) and sealed with coverslip. Analysis performed using a Nikon C1 (Nikon, 
NY) confocal microscope within the Imaging Core Facility in the Hamilton Eye Institute. 
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Optic nerve processing, imaging and counting 
 
 Eyes along with optic nerves were enucleated from mice immediately after 
euthanasia. Optic nerves were cut close to the globe and were fixed in 0.8% 
paraformaldehyde and 1.22% glutaraldehyde in 0.08 M phosphate buffer. They were 
subsequently rinsed in buffer and post-fixed in 1% osmium tetroxide. After dehydration, 
the specimens were embedded in Epon 812 plastic. Sections (0.8μm thick) were cut on 
an ultramicrotome (Reichert-Jung Ultracut E Ultramicrotome), stained with p-
phenylenediamine (PPD) for 30 min. Digital images were taken using 10x and 4x 
objectives using a MicroFire digital camera (Optronics®, Goleta, CA) mounted onto a 
Nikon Eclipse E800 light microscope (Nikon). Multiple contiguous photomicrographs 
were taken at 60x magnification to provide a continuous representation across the optic 
nerve. A scale of optic nerve damage similar to that used by Clark and colleagues was 
used to assign a numeric value to the appearance of the nerve (David Cantu-Crouch, Iok-
Hou Pang, Mitchell D. McCartney, Abbot F. Clark; unpublished protocol). The numeric 
value is based upon the presence/absence of darkly stained axoplasm and presence of 
gliotic scars. 
 
 
IOP measurements 
 
 IOP was measured using the induction–impact tonometer (Tonolab tonometer, 
Colonial Medical Supply, Franconia, NH) for rodents according to the manufacturer’s 
recommended procedures. When measuring IOP, the tonometer was fixed in a vertical 
position to a support stand by means of clamps. The mouse was gently restrained by hand 
on an adjustable stand, and the eye was oriented in such a way that a distance of 1–4 mm 
was maintained between from the tip the probe to the cornea of the eye. Six consecutive 
IOP readings were averaged. IOP readings obtained with Tonolab have been shown to be 
accurate and reproducible in various mouse strains, including DBA/2J. 
 
 
Results 
 
 
The Thy1+CD48neg surface phenotype is not sufficient to identify murine RGCs 
 
 Murine retinal cells express two distinct isoforms of Thy1Thy1.1 and Thy1.2 
(218-220). We compared the binding of Thy1.1 and Thy1.2 to dissociated murine retinal 
cells and show the majority of murine retinal cells exhibit immunoreactivity against 
Thy1.2 but not Thy1.1 (Figure 4-2, Thy1.2+ at 53.9% versus Thy1.1+ at 1.7%). Current 
RGC isolation techniques use selection based on Thy1-positivity and CD48-negativity by 
antibody-capture (209, 210) or magnetic cell isolation (211, 213). Our data demonstrate 
that a small percent of Thy1.2+ cells were also immunopositive for CD48 (11.2%) and 
that inclusion of CD48 as a negative selection marker did not significantly decrease the 
number of Thy1.2+ cells (Figure 4-3, left panel). To determine if the Thy1.2+CD48neg 
cells were RGCs, we probed the cells for the expression of the RGC signature marker -  
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Figure 4-2. Thy1+CD48neg surface phenotype is not sufficient to identify murine 
RGCs 
 
Left panel: Pseudocolor plots were gated on live nucleated cells based on FSC and SSC 
profiles. Based upon these characteristics, 84.6% of the cells were live after retinal 
dissociation. Middle panel: A negligible number of live retinal cells were Thy1.1+ 
(1.1%), whereas 53.9% were Thy1.2+, demonstrating that in mouse Thy1.2 is the 
preferred surface marker. Right panel: The majority of the Thy1.2+ cells (88%) were 
CD48neg. 
 
 
 
 
 
 
Figure 4-3. Lack of specificity of current RGC isolation methods 
 
There was no significant difference in the percent of live Thy1.2+ and Live 
Thy1.2+CD48neg cells demonstrating that the addition of CD48 as a negative selection 
marker is insufficient to further enrich for RGCs. Only 60% of LiveThy1.2+CD48neg are 
SNCG+ indicating that many contaminating cell types remain in the LiveThy1.2+CD48neg 
cell population. Gray histogram represents control and black line represents experimental 
sample. 
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synuclein (SNCG). Consistently, we found that a large proportion of Thy1.2+CD48neg 
cells were not SNCG+. Figure 4-3 right panel, illustrates that 60% of Live 
Thy1.2+CD48neg cells were positive for SNCG, suggesting that there is ~40% 
contamination by non-SNCG+ cell types. To address which non-RGC cell types are 
present within the Thy1.2+CD48negSNCGneg phenotype, we performed qPCR analysis on 
the sorted cells. Using the absolute quantification method, we determined the optimal 
concentration of pre-amplified samples that would be suitable for our validation step and 
calculated the efficiency of amplification (Figure 4-4). Our qPCR method is presented in 
Figure 4-4. Results shown in Figure 4-5 reveal the degree of heterogeneity of the 
enriched RGCs using only Thy1.2 and CD48 as surface markers. Specifically, 
Thy1.2+CD48neg cells expressed genes associated with multiple retinal cells, including 
amacrine, Müller, bipolar, horizontal, photoreceptors and retinal pigment epithelial cells. 
Table 4-1 lists the specific genes associated with the various cell types. Our data 
demonstrates that selection based solely on Thy1 and CD48 expression is insufficient to 
isolate highly enriched RGCs. 
 
 
Confirmation of additional surface markers to be used as negative selectors and 
intracellular RGC markers 
 
 We used IHC to determine the retinal localization patterns of other surface 
markers that were expressed by contaminating cells. CD15 has been described as a 
marker of retinal interneurons including amacrine and bipolar cells (221), while CD57 
has been shown to label glial cells and photoreceptors (222). Our data demonstrate that 
CD15 (Figure 4-6A) is localized in the interface between the inner nuclear layer (INL) 
and inner plexiform layer (IPL) and in the proximal INL (arrows), where amacrine cells 
are located. Occasional CD15+ cells were observed in the ganglion cell layer (GCL), 
which are most likely displaced amacrine cells (arrows). CD57 immunoreactivity (Figure 
4-6B) was abundant in the outer plexiform layer (OPL) and in a radial pattern through the 
INL. Punctate staining was also present in the GCL, which are likely astrocytes or 
displaced amacrine cells. Collectively, these results show that these surface 
markersCD15 and CD57can be used as negative selectors to remove non-RGCs 
from the Thy1.2+CD48neg cell population. 
 
 To verify that the commonly accepted RGC intracellular markers are specific for 
RGCs (175, 208, 212, 223), we labeled murine retinal sections with antibodies against 
SNCG, BRN3A [Brain-specific homeobox/POU domain protein 3A (Pouf4l)], TUJ1 
[neuron-specific class III beta tubulin (Tubb3)] and RBPMS [RNA binding protein with 
multiple splicing (Rbpms)]. SNCG showed abundant expression in the GCL (Figure  
4-7A). Abundant BRN3A (Figures 4-7B) labeling was observed in the GCL. However, 
multiple cells in the INL that border the IPL are also immunopositive for BRN3A. Based 
upon their location, they are likely amacrine cells. TUJ1 (Figure 4-7C) was very 
abundant in the GCL and in radial labeling patterns throughout the retina that extend up 
to the ONL. Lastly, RBPMS was highly expressed by cells in the GCL (Figure 4-7D) 
and a small subpopulation of cells in the INL (arrow). Collectively, these data 
demonstrate that SNCG-, BRN3A-, TUJ1- and RBPMS-positive cells are present in the   
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Figure 4-4. Validation of our improved protocol for the enrichment of RGCs 
 
(A) Schematic representation of our validation analyses of Live 
Thy1.2+CD48negCD15negCD57neg sorted cells. (B) Amplification and standard curves to 
evaluate primer efficiency. Left panel: amplification curves of the ten-fold dilution series 
for all the primers. Right panel: Standard curves depicting CT plotted against the log of 
the starting quantity of template for each dilution. The efficiency of the all PCR reactions 
was between 90–100% (−3.6 ≥ slope ≥ −3.3). All samples were prepared and analyzed in 
triplicate. 
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Figure 4-5. Identification of Thy1.2+CD48neg cells using qualitative real time PCR 
analysis 
 
The expression levels of a panel of 25 genes expressed by various retinal cell 
typesamacrine, Müller, bipolar, horizontal, photoreceptor and retinal pigment epithelial 
cellsin Thy1.2+CD48neg cells were normalized to the levels present in unsorted total 
retinal cells. The Thy1.2+CD48neg population showed contamination with other retinal 
cell types. Target gene expression levels are presented as Log2 fold change based on the 
ΔCT calculation using Hprt as a housekeeping gene and water as negative control. 
MeanSEM.  
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Table 4-1. Genes used in gene expression analyses as part of the validation of our 
RGC enrichment protocol 
 
Retinal Cell Type Genes Expressed by Retinal Cell Type 
Retinal Ganglion Cell Pou4f1; Rbpms; Sncg; Tubb3; Chrma6; Rbfox3; 
Nef-H 
Amacrine Gad2; Fut4; Calb2; Pvalb; Slc6a9; Pcp4; Vip; 
Thy1 
Astrocytes Aqp4; Prdx6; Gfap; Slc1a3; Pax2 
Müller ApoE; Abca8a; Vim; Aldh1a1 
Bipolar PkcaPcp4; Rcvrn; Slc1a2 
Horizontal Rcvrn; Prox1; Ntrk1; Lhx1, Lim2, Calb2 
Photoreceptors (Cone and Rod) Nrl; Rom-1; Crx; Pxph2; Arr3 
Retinal Pigment Epithelial Cells Cd68; Rpe65 
Housekeeping Gene Hprt 
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Figure 4-6. Immunohistochemical localization of surface antigens used in our 
RGC sorting protocol 
 
Cellular localization of the surface proteins CD15 and CD57 in retinae from C57BL/6J 
mice. Sections from C57BL/6J mouse retinae were labeled with antibodies against (A) 
CD15 and (B) CD57. TO-PRO-III iodide staining labeled nuclei of all retinal cells (blue). 
Abbreviations: GCL=ganglion cell layer; IPL=inner plexiform layer; INL=inner nuclear 
layer; OPL=outer plexiform layer; ONL=outer nuclear layer. Scale bar: 10μm. 
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Figure 4-7. Immunohistochemical localization of intracellular RGC markers used 
as part of the validation process of our sorting protocol 
 
Cellular localization of intracellular proteins SNCG, BRN3A, TUJ1 and RBPMS in 
retinae from C57BL/6J mice. Sections from C57BL/6J mouse retinae were labeled with 
antibodies against (C) SNCG, (D) BRN3A, (E) TUJ1, and (F) RBPMS. TO-PRO-III 
iodide staining labeled nuclei of all retinal cells (blue). Abbreviations: GCL=ganglion 
cell layer; IPL=inner plexiform layer; INL=inner nuclear layer; OPL=outer plexiform 
layer; ONL=outer nuclear layer. Scale bar: 10μm. 
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GCL and can be used to validate the identity of the cells that we isolate using our array of 
cell surface markers. Even though BRN3A and RBPMS also label a small subset of 
(likely) amacrine cells, we are confident that requiring all enriched RGCs to express all 
four RGC markers will yield a nearly pure RGC population. 
 
 
Live Thy1.2+CD48negCD15negCD57neg RGC express all signature intracellular 
markers SNGC, BRN3A, TUJ1 and RBPMS 
 
 Our expanded cell sorting strategy is presented in Figure 4-8. Because 
Thy1.2+CD48neg cells expressed many markers associated with retinal cells other than 
RGCs, we added additional surface markersCD15 and CD57to our sorting strategy 
to remove these contaminating cells. Our methodology included the negative selection of 
these cell surface markers to enrich for naïve RGCs that could be used in downstream 
analyses. Collectively, we were targeting the removal of monocytes, as well as glial, 
amacrine and photoreceptor cells. Prior to cell surface labeling, we added purified mouse 
anti-CD16/32 antibody to block FcRII/III, thus reducing false positive immunoreactivity 
(224) (224, 225). Our flow cytometry-based cell sorting validation studies included 
examination of pre- (Figure 4-9) and post-sorted cells (Figure 4-10) to confirm that the 
post-sorted cells that were isolated using cell surface markers expressed all four RGC 
intracellular markers: SNCG, BRN3A, and TUJ1, and RBPMS. Consistently, we 
observed 99-100% positivity for all of the intracellular markers in the post-sorted cells, 
demonstrating the isolated cells were very highly enriched, if not pure RGCs. We ensured 
consistency of our results across multiple systems using two other cytometer systems, the 
MACSQuant® Analyzer 10 and the FlowSight®. Our novel method was standardized as 
we obtained reproducible results (Figure 4-11, Figure 4-12). 
 
 Using confocal microscopy, we investigated the morphological appearance of the 
sorted cells. Live Thy1.2+CD48negCD15negCD57neg cells were stained with SYTO® 59 
dye showing nuclear integrity. Cells showed bright blue fluorescence and strong 
intracellular staining (Figure 4-13). This result confirms 
LiveThy1.2+CD48negCD15negCD57neg sorted cells show the morphology associated with 
RGC. 
 
 
Validation of the enriched RGC population by qPCR analyses 
 
 Qualitative PCR analyses (Figure 4-14) shows that the highly enriched RGC 
population had a many fold increase in the expression of all four RGC intracellular 
markers: Sncg, Pouf4l, Tubb3 and Rbpms. As expected, genes found in other retinal cells 
were expressed at significantly lower levels than in unsorted retinal cells. Moreover, our 
improved sorting methodology removed the contaminating retinal cell types that were 
present in the Thy1.2+CD48neg cells (compare Figure 4-5 and Figure 4-14). These 
mRNA analyses further validated our RGC enrichment strategy. 
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Figure 4-8. Optimized FACS-based cell sorting strategy 
 
Schematic representation of RGC isolation by flow cytometry using multiple surface 
markers. Step 1: Cells were labeled with Zombie Aqua™ for live/dead cell analysis 
followed by step 2: blocking of FcRII/III (mouse anti-CD16/32) to minimize non-
specific labeling. Step 3: Cell surface labeling was performed using the following 
antibody cocktail: anti-mouse anti-CD90.2 Alexa Fluor 700; anti-CD48 PE-Cy7; anti-
CD15 PE and anti-CD57 Brilliant Violet 421 to yield 
LiveThy1.2+CD48negCD15negCD57neg cells.  Single labeled fluorochrome-beads were 
used as controls. 
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Figure 4-9. Surface marker expression of pre-sorted retinal cells 
 
Far left panel: Live retinal cells show two distinct populations of Thy1.2 (Thy1.2hi and 
Thy1.2low) based upon expression levels per cell.  Right panels: Representative FACS 
plots show the expression of surface markers used for negative selectionCD48, CD15, 
CD57in pre-sorted Thy1.2hi and Thy1.2low retinal cells. Labeled retinal cells were 
sorted for Thy1.2hiCD48negCD15negCD57neg population. Selection for sorting included the 
positive selection of Thy1.2hi (36%). This population was further selected for CD48neg 
(3%), followed by CD15neg (20%) and CD57neg (36%).  Grey indicates isotype controls, 
colored solid lines indicates experimental samples. 
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Figure 4-10. Purity of post-sorted RGCs based on the surface marker and 
intracellular RGC markers 
 
Far left panel: LiveThy1.2+CD48negCD15negCD57neg cells show expression of Thy1.2+ 
(95%). Top right panels present representative FACS plots show the negligible 
expression of surface markers in sorted LiveThy1.2+CD48negCD15negCD57neg cells, 
demonstrating the efficiency of the sort. Lower row panels show representative FACS 
plots of the expression of intracellular RGC markers in 
LiveThy1.2+CD48negCD15negCD57neg cells. 99-100% of all cells express SNCG, BRN3A, 
TUJ1 and RBPMS, all well characterized RGC markers. This new sorting method 
(Thy1.2hiCD48negCD15negCD57neg) shows improvement over the previously used 
methodology (LiveThy1.2+CD48neg) using additional surface markers. Grey indicates 
isotype controls, colored solid lines indicates experimental samples. 
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Figure 4-11. Consistency of flow cytometry results using MACSQuant® 
 
Dissociated murine retinal cells from C57BL/6J mice were labeled for cell surface 
markers based on the sorting protocol. Sample was acquired using a MACSQuant® 
Analyzer 10 from Miltenyi Biotec. Results show consistency between the two different 
cytometers (BD FACS Aria and MACSQuant®). 
 
 
 
 
 
 
Figure 4-12. Intracellular expression of the RGC marker RBPMS in Live 
Thy1.2+CD48negCD15negCD57neg cells 
 
Representative images from a cohort of 250,000 pictures at 20x of cells using the 
FlowSight® Imager. Results show the expression of Thy1.2 surface and RBPMS 
intracellular markers. 
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Figure 4-13. Live Thy1.2+CD48negCD15negCD57neg show RGC morphology 
 
(A) Representative image of sorted cells after cultured overnight at 37°C/5%CO2 in RGC 
culture media showing RGC-type morphology. (B) Representative images of sorted cells, 
immediately after sort. 
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Figure 4-14. Validation of Live Thy1.2+CD48negCD15negCD57neg cells using qPCR 
analyses 
 
Graph depicts expression of different retinal cells markers in  
Live Thy1.2+CD48negCD15negCD57neg that were normalized to the mRNA expression 
measured in total primary murine retinal cells. Genes associated with RGCsSncg, 
Pouf41, Tubb3 and Rbpmsshowed increased gene expression or mRNA transcripts 
compared to non-RGC associated genes. Target gene expression levels are presented as 
Log2 fold change based on CT calculation using Hprt as housekeeping gene. Mean ± 
SEM; n=3 biological replicates were performed in triplicate. 
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Highly enriched RGCs can be isolated from a mouse model with elevated IOP and 
optic nerve damage 
 
 We sought to apply our improved RGC isolation methodology on a retinal 
degenerative disease model. Members of our research group have analyzed a family of 
over 100 BXD (68) murine strains and their parental strainsC57BL/6J and DBA/2Jat 
5 different age cohorts to determine which strains had the phenotype of optic nerve 
damage and elevated IOP (IOP). Both of these phenotypes are associated with retinal 
degeneration in glaucoma. Our examination revealed that the BXD66 strain had both 
elevated IOP and higher optic nerve damage compared to both C57BL/6J and DBA/2J 
parental strains of mice (Figure 4-15). In addition, the optic nerves of old BXD66 mice 
had an increase in axon damage and glial scarring compared to young C57L/6J and 
BXD66 mice. Figure 4-16 depicts representative micrographs showing optic nerve 
damage. 
 
 To determine if our RGC protocol was valid using retinae with damaged RGCs, 
we applied our optimized and validated enrichment strategy on retinae obtained from 
young and old BXD66 mice. We compared two different ages to investigate if our 
enrichment protocol could be used on mice with compromised RGCs and if the efficiency 
of the strategy was age dependent. We first compared the cellularity of retinal cells and 
the percentage of live cells between the two ages of mice. Selecting for the phenotype 
LiveThy1.2+CD48negCD15negCD57neg, enriched RGCs (Figure 4-17) were examined for 
the presence of the same signature intracellular RGC markers that we used throughout 
this investigation. Figure 4-18 shows the intracellular staining pattern in young and old 
BXD66 mouse retinas. Similar to that found in C57BL/6J mice, the majority of the 
enriched cells from BXD66 mice are immunoreactive toward the four intracellular RGC 
markers (Figure 4-19). However, we observed a slight reduction in TUJ1 in BXD66 
young and old mice compared to the C57BL/6J parental line, which may be indicative of 
RGC damage in this model. When comparing the total number of retinal cells (obtained 
from retinae of young and old C57BL/6J and BXD66 mice) with those of the phenotype 
LiveThy1.2+CD48negCD15negCD57neg, we found similar patterns of changes (compares 
both panels in Figure 4-20A). Within a strain, retinae from old mice had fewer live 
retinal cells than young mice. In addition, retinae from BXD66 mice had a reduced 
number of retinal cells compared to age-matched C57BL/6J mice (Figure 4-20B). 
Moreover, old C57BL/6J mice had a lower percentage of 
Thy1.2hiCD48negCD15negCD57neg retinal cells compared to young mice (0.9%±0.3 in 
young mice compared to 0.5%±0.3 in old mice, p=0.041, Figure 4-20B). We consistently 
found a marked reduction in the number of live retinal cells between BXD66 old (>12 
months old) and young (5 weeks old) mice (Figure 4-20; live cells young versus old: 
80% versus 48%). It is worth noting that the percentage of live cells isolated from young 
pre-degenerative BXD66 mice is comparable to that obtained from young C57BL/6J 
mice (compare to Figure 4-2). Retinae from young BXD66 mice also had a higher, but 
not significantly different, percentage of Thy1.2hiCD48negCD15negCD57neg cells 
compared to old BXD66 mice (0.4%±0.3 in young mice compared to 0.2%±0.2 in old 
mice, p=0.177). Lastly, there was a significant reduction in the percentage of   
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Figure 4-15.  Fewer RGCs are harvested from mice with documented 
elevated IOP and optic nerve damage 
 
Peak IOP and optic nerve damage distributions for C57BL/6J, DBA/2J and BXD66 mice. 
BXD66 mice had significantly higher peak IOP (blue bars) and optic nerve damage (pink 
bars) compared to C57BL/6J mice (**p<0.005 between B6 and BXD66 IOP values; ## 
p<0.005 between B6 and BXD66 optic nerve damage grade). Mean ± SEM; n =4 per 
group. 
 
 
 
 
 
 
Figure 4-16. Optic nerve damage in C57BL/6J and BXD66 young/ old mice 
 
Representative PPD-stained optic nerve cross-sections from C57BL/6J (young: 5-7 
weeks old), BXD66 (young: 5 weeks old), and BXD66 (>12 months old) mice. Both 
young C57BL/6J and BXD66 mice had a low degree of damage. In contrast, optic nerves 
from old BXD66 mice presented with disorganized axon bundles, increased glial scarring 
and multiple dead/dying axons. Scale bar=10μm. 
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Figure 4-17. Characterization of enriched RGCs from young and old BXD66 mice 
obtained through our improved flow sorting method 
 
Representative histograms show comparison of surface expression of Thy1.2, CD48, 
CD15 and CD57 in total retinal cells of young versus old BXD66 mice. Top panel: In 
BXD66 young mice, live retinal cells have the following abundance levels: Thy1.2 
(56%), CD48 (63%), CD15 (81%) and CD57 (66%). Bottom panel: In BXD66 old mice, 
live retinal cells have the following abundance levels: Thy1.2 (41%), CD48 (77%), CD15 
(80%) and CD57 (50%). Gray histogram indicates isotype controls; black solid lines 
indicates antibody labeling. 
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Figure 4-18. Localization of known intracellular RGC markers in BXD66 
young/old mice 
 
SNCG, BRN3A, TUJ1 and RBPMS in retinae from young and old BXD66 mice. 
Sections from young and old BXD66 mouse retinae were labeled with antibodies against 
(C) SNCG, (D) BRN3A, (E) TUJ1, and (F) RBPMS. TO-PRO-III iodide staining labeled 
nuclei of all retinal cells (blue). Abbreviations: GCL=ganglion cell layer; IPL=inner 
plexiform layer; INL=inner nuclear layer; OPL=outer plexiform layer; ONL=outer 
nuclear layer. Scale bar: 10μm. 
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Figure 4-19. Relative purity of sorted RGCs based upon surface marker selection 
and intracellular RGC markers 
 
Representative histograms show comparison of intracellular expression of RGC markers 
SNCG, BRN3A, TUJ1 and RBPMS in Live Thy1.2+CD48negCD15negCD57neg cells of 
young and old BXD66 mice. Top panel: In BXD66 young mice have the following 
abundance levels: SNCG (100%), BRN3A (100%), TUJ1 (90%) and RBPMS (100%). 
Bottom panel: In BXD66 old mice have the following abundance levels: SNCG (98%), 
BRN3A (100%), TUJ1 (95%) and RBPMS (100%). Gray histogram indicates isotype 
controls; black solid lines indicates antibody labeling. 
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Figure 4-20. Comparison of live retinal cells based on sorting protocol 
 
Percentage of Live Thy1.2+CD48negCD15negCD57neg cells in retinae from C57BL/6J 
(young and old) and BXD66 (young and old) mice. **p<0.005; *p<0.05 compared to 
young C57BL/6J mice. Mean±SEM; n=3 per group. 
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compared to 0.4%±0.3 in BXD66 mice, p=0.024). Collectively, our data show that our 
improved RGC enrichment protocol is also effective on retinae from old mice with no 
retinal degeneration (C57BL/6J) and in mice with a phenotype of elevated IOP and RGC 
damage (BXD66). 
 
 
Discussion 
 
 A common element of the pathophysiology of several retinal neurodegenerations 
is the loss of ganglion cells and their axons (14). Understanding of the mechanisms 
underlying these processes is limited by the lack of a simple in vitro system with which to 
study RGC function. This is in part is due to the scarce number of RGCs and the 
heterogeneity present among the current cellular enrichment protocols. The use of 
antibody-dependent plate adhesion, or immunopanning, originated more than 35 years 
ago when it was used for the enrichment of immune cells. Barres and colleagues (209) 
utilized the immunopanning system wherein they used Thy1 and CD48 to isolate RGCs. 
They demonstrate the following three points: 1) Thy1 is not an exclusive marker of 
murine or rat RGCs, as other Thy1+ retinal cells do not show the morphology and/or 
electrophysiological characteristics of RGCs; 2) there is variation in the expression of 
Thy1 positivity among RGCs; and 3) this assay only produced a 95% efficiency based on 
Thy1 expression. This classical study allowed for the first time the use of immune 
techniques in the field of neuroscience. Prior to the publishing of this methodology, RGC 
isolation was based on density gradient centrifugation with varying yield degrees (226-
228). Although inexpensive and rapid, a major drawback of Barres’s methodology was 
that it required the retrograde labeling of fast blue into both superior collicular and 
brachia 48-hrs prior to retinal dissection. In 1999, Shoge and colleagues (229) developed 
a protocol for the enrichment of rat RGCs based on magnetic cell separation via inclusion 
of Thy1+ cells and the exclusion of macrophages. This method became popular because it 
provided a fast method for enrichment of rat RGCs, although it required magnetic 
columns and magnetic drivers for the separation. Unfortunately, their RGC enrichment 
was only 31% indicating that many contaminating cells are present. Recently, Hong and 
colleagues (210) combined the immunopanning and magnetic cell sorter techniques to 
isolate murine postnatal (P1-4) RGCs. However, because the success of the method was 
based solely on exclusion of glial fibrillary acidic protein and synthaxin 1, the purity of 
the RGCs that were isolated is unknown. 
 
 We sought to develop an improved RGC enrichment strategy that could be used 
by most investigators without the requirement for retrograde labeling that may alter the 
physiology of RGCs. Our protocol also does not include immunopanning which is 
lengthy. Our method is rapid and requires only five hours from the initiation of retinal 
dissection to the completion of fluorescence activated cell sorting. Because of the 
exquisite sensitivity of the method, FACS-based sorting is suited for purification of cells 
that comprise a very small percentage within a cell suspension. Thus, the procedure is 
ideal for the isolation and enrichment of RGCs, estimated to be about 0.5% of retinal 
cells (148, 204). A caveat of our methodology is the requirement of expensive FACS 
instrumentation, and the need for highly trained and specialized operator. However, most 
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academic and research facilities have flow cytometry core facilities, which should make 
this method accessible to most investigators. FACS-based sorting has a tremendous 
versatility because of the large number of selection markers that can be used in the 
enrichment process. Typically, the selection is based on 2 to 15 complementary 
parameters, which allow for acquisition of a reproducible and homogeneous phenotype 
within a sample and between samples that can be used in follow up in vitro studies. This 
methodology also allows for the immediate identification of viable cells and excludes 
cells that are undergoing apoptosis or are already dead. In addition, the inclusion of an Fc 
receptor blocker allows for exclusion of microglia, monocytes and macrophages, which 
results in a higher degree of RGCs. Post-sorting analysis of enriched RGCs indicated cell 
viability was 95%, confirming that external high pressure (60-70 psi) exerted on cells 
during FACS had a negligible effect on their viability. Lastly, another advantage of this 
methodology is the immediate verification of the sort purity, as it only takes as small 
aliquot of the isolated product to verify the surface phenotype. 
 
 As part of our RGC enrichment strategy, we incorporated robust validation 
components. For example, within our validation studies, we use immunohistochemistry 
to validate two additional surface markersCD15 and CD57that improved the 
efficiency of our sorting strategy. In addition, the stringency of FACS validation strategy 
was confirmed using four RGC specific intracellular markersSncg, Pouf4l, Tubb3, and 
Rbpms, which encode for SNCG, BRN3A, TUJ1, and RBPMS, respectivelyboth at the 
protein and mRNA level. Furthermore, we identified the presence of non-RGCs using 
multiple genes expressed by other retinal cell types using qPCR analyses. To our 
knowledge, this is the first time, such a stringent validation process using both gene 
expression (qPCR) and protein (flow cytometry and immunohistochemistry) analyses 
have been performed on isolated and enriched murine RGCs. 
 
 As a further validation of the applicability of our enrichment protocol, we 
evaluated the ability of our RGC enrichment strategy to isolate RGCs from a mouse 
model with elevated IOP and optic nerve damage. Members of our collaborative group 
use the BXD family of RI mice for gene mapping and quantitative trait locus QTL 
analyses to identify specific genomic regions that modulate various glaucoma-associated 
endophenotypes (59, 82, 230). The BXD RI strains are derived by inbreeding the 
C57BL/6J and DBA/2J parental strains. BXD mice have been successfully used in vision 
research to elucidate specific cause-effect predictions between genes and a quantitative 
phenotype, such as differences in expression levels (68, 70, 82, 119). In these studies, we 
selected the BXD66 strain due to its age-dependent elevation in IOP and optic nerve 
damage (not published but available on www.GeneNetwork.org). Our intracellular flow 
cytometry protein analysis revealed a similar percentage of cells that show positivity for 
the surface marker Thy1.2, while negative selection of CD48, CD15 and CD57, and 
concomitant positivity for the intracellular markersSNCG, BRN3A, TUJ1, and 
RBPMSin both C57BL/6J mice and BXD66, irrespective of the age bin (5 weeks 
versus 12 months). Nonetheless, the percentage of RGCs was significantly lower in the 
BXD66 mice compared to the C57BL/6J mice, suggesting that RGCs, a population that is 
already scarce in the mammalian retina, is less abundant in BXD66 mice. Our data also 
highlight variation in the expression of TUJ1 in RGCs isolated from BXD66 mice at 
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different ages, suggesting that differences in TUJ1 levels likely reflect altered physiology 
of the damaged RGCs, rather than the absence of RGCs in these mice. 
 
 In summary, we demonstrate a powerful technique for the isolation and 
enrichment of primary murine RGC with the phenotype Live 
Thy1.2hiCD48negCD15negCD57neg, which concomitantly express the RGC signature 
intracellular markers SNCG, RBPMS, TUJ1, and BRN3A. These cells can be used for 
controlled in vitro studies of RGCs derived from healthy and disease models. The 
streamlined and effective isolation and validation method described here will facilitate 
subsequent research on the pathological and pharmacological processes with clinical 
relevance to diseases involving RGCs. 
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CHAPTER 5.    DISCUSSION AND CONCLUSION 
 
 
Future Directions 
 
 
Aim1: To identify the candidate gene that modulates IOP in mouse and test 
translational validity of the mouse candidates using the cohorts of human glaucoma 
patients 
 
 The main characteristic feature of glaucoma is the progressive and relatively slow 
damage/death of RGCs (1). Ganglion cell death is also a feature of a number of other 
optic neuropathies and retinopathies apart from glaucoma. The known acute induced 
models that are currently used include, optic nerve crush, ischemia/reperfusion injury, 
excitotoxic damage etcetera; are useful only in some aspects for glaucoma research (231). 
The injury caused in these models is not just a specific damage to RGCs but a general 
injury to the whole retina, therefore these models resembles more closely to other 
diseases than glaucoma. To study such a progressive disease, the most relevant rodent 
glaucoma model should include chronic elevation of IOP, to study high tension 
glaucoma. Due to the difficulty in reproducing a standardized chronic elevated IOP 
model thus far in the rodents, a main focus of interest should be to discover rodent strains 
with spontaneously elevated IOP. 
 
 The mouse models with chronic IOP that are currently available are mostly knock 
out models with single gene mutations, such Mendalian mutations do not correlate with 
human glaucoma (231). In the past decade and a half dramatic advances has been seen in 
the field of glaucoma research due the introduction of chronic inherited disease in inbred 
mice strains. DBA/2J inbred line is the most well characterized mouse model of 
glaucoma (64). Although this model has been extensively studied, few limitations makes 
this model not ideal for studying glaucoma. In these animals, the glaucoma progression is 
not due elevated IOP. The disease progression is in fact due to the secondary systemic 
pigment dispersion syndrome with the associated mutations in the Gpnmb and Tyrp1 loci. 
The natural history of disease in DBA/2J mice varies, depending on individual colonies 
and other environmental factors. Also, even though these are inbred mice with a fixed 
genetic background, they still exhibit a high degree of variability and asymmetry in 
developing the disease. Only about 70% of the animals develop glaucoma since both of 
these genes show incomplete penetrance (66, 67). 
 
 Because BXD mice are genetically stable inbred lines, this makes them an 
informative tool for understanding human disease. The combined BXD strain set is the 
largest existing mouse RI mapping panel. Using a systems genetics approach, we and 
other researchers have successfully used BXD RI murine panel for studying genetic 
modulators and identifying non-synonymous polymorphisms for complex polygenetic 
diseases such as glaucoma, pigment dispersion syndrome, hypertension, and metabolic 
disorders system (69-71). RI strains are especially useful for mapping complex traits, 
since they create an immortalized mapping population that allows us to phenotype as 
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many animals per genome as desired over extended periods of time which leads to more 
precise phenotypic estimates invaluable to mapping complex disease traits as glaucoma. 
Using this information, we can identify specific wild type BXD strains (i.e., no Tyrp1 and 
Gpnmb mutations) that have elevated IOP, high optic nerve damage and iris defects that 
can be used as high tension glaucoma model. We can also distinguish the strains based on 
IOP and optic nerve damage grades to identify normal tension glaucoma models. Such 
mouse models would be ideal to study glaucoma progression, since these mice will not 
have any influence of Tyrp1 and Gpnmb genes, and natural variations due to 
recombination events would ideally represent human disease states such as POAG. 
 
 Genetic studies using BXD mice are proving to be a powerful means to study 
disease causing genes and pathologic mechanisms that cause disease or alter disease 
susceptibility. The systems genetics approach has been widely used to identify the 
genetic basis for pharmacogenetic traits and becomes increasingly more powerful with 
the recent advances in genomic technologies. We can easily study a genetic association 
with drug response if there is a plausible link between the gene and the drug response. 
We can characterize physiological or pharmacologic effects of the genes (or genetic 
variations) on disease or drug response. In spite of increased spending on pharmaceutical 
research and development, the number of ‛new’ drug approvals for glaucoma has 
remained relatively constant. The essential first step in the drug discovery pipeline is the 
identification and early validation of disease-modifying targets. In recent years ‛systems’ 
approach has become popular to identify new targets to understand the cellular 
mechanisms underlying a particular disease. The systems approach is geared towards 
target-discovery through the study of disease in whole organisms such as mice or rats 
(232). Here, we used ‛systems genetics’ to identify IOP-associated genes. In future we 
can validate these as functional targets, and utilize such approach in bridging the gap 
between data generation and effective drug target identification. In this study, the 
identification of a novel candidateCACNA2D1linked to elevated IOP was an 
exemplar to pave the way for improved drug development tailored to individuals with 
glaucoma leading to personalized medicine. The outcomes of these investigations will 
identify a novel therapeutic for IOP reduction that specifically targets a gene product that 
was identified in bidirectional POAG studies. They will also determine if the genotype 
influences response to therapy. Such results are expected to fundamentally advance the 
field of glaucoma therapy, which will have positive translational impact. 
 
 Our Aim 1 studies are innovative for at least the following five reasons: 
1. We have utilized a large number of aging BXD strains that are segregating for 
glaucoma susceptibly genes. The DBA/2J strain has been used as the standard 
model for pigmentary dispersion glaucoma by a substantial number of 
investigators. We have greatly enriched this field by introducing new variant 
strains that have both Tyrp1 and Gpnmb mutations and new strains with wild type 
genotypes that have a highly variable disease state. Our set of 66 aging BXD 
strains is sufficiently large to allow us to identify loci, and even genes, that cause 
glaucoma. 
2. We used the complete sequence data for DBA/2J and the dense genotypes for all 
BXD strains. We now have a database of ~4M SNPs, 400K indels, and thousands 
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of inversions and CNVs that are segregating among the BXD strains. The 
consequence of this is that our QTL analysis and the massive genomic/genetic 
data led to more efficient extraction of functional sequence variants linked to IOP. 
3. We used a novel systems genetics approach to help define molecular networks 
that modulate IOP. By using the eye transcriptome data and aging BXD IOP 
phenotype data, we were able to assemble gene-phenotype networks. This is one 
of the most exciting aspects and is a departure from the typical experimental 
paradigm of testing and comparing knockout and wildtype mouse models of 
human disease. This project represents a novel application of the use of 
expression genetics in dissecting the transcriptome predictors of IOP and other 
phenotypes associated with glaucoma. 
4. We have combined mouse data sets with data from human GWA studies in a 
bidirectional manner to identify a candidate gene most likely to modulate IOP. 
5. We provide the scientific community with a novel gene 
candidateCACNA2D1that influences IOP based upon a systems genetics 
approach by using BXD strains. 
 
 
Aim 2: To identify and validate regulator of Sncg in primary mouse RGCs 
 
 Glaucoma is characterized by ON axon loss and RGC degeneration and is often 
linked with elevated IOP. In a complex disease such as glaucoma, the molecular 
processes driving the complex disease usually affects genes acting in concert. One of the 
strategies that we used for these studies was systemslevel approaches to investigate 
transcriptional networks and pathways within pathologically relevant cellsRGCs. Our 
integrated analysis of transcriptional networks associated with Sncg susceptibility data 
and phenotypic information allowed us to identify specific pathways to be connected to 
disease states, and thereby can identify disease pathways and their genetic regulators as 
new targets for therapeutic intervention. We took the full advantage of the BXD RI 
strains in combination with a powerful combination of systems biology, microarray 
analysis, expression genetics, bioinformatics along with conventional techniques to study 
mechanism of gene regulation. 
 
 Although the molecular mechanisms responsible for RGC death is not well 
known, considerable evidence suggests the involvement of synuclein as a component 
of RGC death. Recent evidence shows that mitochondrial dysfunction is present in some 
glaucoma patients. POAG patients have been reported to have increased levels of 
mtDNA mutations as well as deficiencies in complex-I driven ATP synthesis and 
respiration (233). Although evidence of mitochondrial dysfunction was reported in 
patients with glaucoma, there is no direct evidence that mitochondrial dysfunction 
contributes to the pathogenesis of glaucoma. In our study the interaction of synuclein 
with mitochondria raises the intriguing possibility that these two components of RGC 
damage might have a synergistic inter-relationship that contributes towards the 
complexities of glaucoma. Possible mechanisms of such an interrelationship include 
synuclein directly or indirectly impairing mitochondrial function, mitochondrial 
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dysfunction exacerbating synuclein levels, or, perhaps, synuclein levels and 
mitochondrial dysfunction enhancing each other in a self-amplifying cycle, or, 
synuclein influencing mitochondrial fission-fusion reaction. Intriguingly the ER is well 
connected, both physically and functionally, to the mitochondria allowing the signaling 
and exchange of metabolites between these two organelles. Since both synuclein and 
prefoldin-2 act as chaperone proteins, their levels may block ER to Golgi membrane 
trafficking. These two chaperone molecules may also perturb microtubule transport 
which may lead to impairment of both the appropriate delivery and distribution of 
mitochondria within RGCs and their axons, particularly from the critical area of the 
synaptic terminals, as well as the disposal of potentially reactive oxygen species 
producing dysfunctional mitochondria. In future such studies will enhance our 
understanding of the pathophysiological mechanisms of mitochondrial dysfunction in 
glaucomatous neurodegeneration, and offer the scientific basis for identifying and 
developing new therapeutic strategies that could protect not only RGCs and their axons, 
but also the central visual pathway against glaucomatous damage. 
 
 Our Aim 2 studies are innovative for the following reasons: 
1. Here, we combined cutting edge methodologies of systems genetics, bidirectional 
studies using multiple species, meta-analyses, immunohistochemistry, FACS 
sorting and gene knockdown studies to identify and validate the identity of a 
genetic modulator of Sncg, a gene that has been previously implicated in RGC 
death in glaucoma. 
2. We exploited partial correlation analysis to solidify the relationship between Sncg 
and Pfdn2 in the mouse retina. The statistically significant partial correlation 
between Sncg and Pfdn2 reflects gene–gene interactions, as well as a regulatory 
relationship between the genes. 
3. We exploited the transcriptome data from both healthy and diseased eyes to 
evaluate the relationship between Sncg and the candidate gene. In healthy retinas, 
the protein levels of both genes are significantly correlated in a positive manner. 
In contrast, the relationship between the genes appears to have changed to an 
inverse relationship with reduced Sncg levels in glaucoma as the disease 
progressed. 
4. Pfdn2 is located in the Qrr1 on chromosome 1, which is a genomic region of 
unusually high gene density and contains major regulatory QTLs for various 
behavioral, metabolic, physiologic and immunological processes including 
diverse epileptic traits(188, 234). This region also controls the expression of a 
remarkably large number of genes, including genes that are associated with some 
of the classical traits that map to distal Chr 1 (e.g., seizure susceptibility). 
5. Knocking down Pfdn2 expression in enriched primary murine RGCs significantly 
reduced the expression of Sncg, confirming that Pfdn2 regulates Sncg expression 
in murine RGCs. The knock down studies were performed in vitro and the cells 
remained alive for 48 hours post-transfection. 
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6. The findings presented in this study provide strong support for the value of 
systems genetics, especially GeneNetwork, in discovering new upstream 
regulators of genes that can be confirmed by molecular analysis. 
 
 
Aim 3: To isolate and validate primary murine RGCs from healthy and 
recombinant inbred mouse model of elevated IOP 
 
 Glaucoma is a complex, multifactorial, neurodegenerative disease that causes 
irreversible vision loss. A universal element in the pathophysiology of the many 
etiologies of glaucoma is the death of RGCs and the degeneration of their axons (1). 
Identifying the genetic basis or cellular mechanisms causing RGC degeneration would be 
the first step toward the development of efficacious therapies to slow or reverse RGC 
damage, in turn preserving vision. But scarce number of RGCs that can be isolated from 
a retina provides a major challenge to develop therapies. 
 
 A great deal has been learned about the cell and molecular biology of glaucoma 
through research on cultured RGCs. However, there are significant limitations with 
current RGC cultures. RGCs are terminally differentiated, and therefore, primary RGCs 
must be prepared from rodent eyes for each experiment conducted. A number of 
laboratories have emphasized the need for having a verified and validated RGC cell line 
to determine the mechanism of RGC cell death or to evaluate therapy efficacies (202, 
203, 235). In attempt to address this need, in 2001, a rat retinal cell line (RGC-5) 
displaying certain characteristics of RGC (expression of the specific cell-type markers 
including Thy1, Brn-3C, neuritin, NMDA receptor, GABA receptor, and 
synaptophysin) was derived by transforming postnatal day 1 rat retinal cells with Ψ2EA1 
virus (236). Multiple questions have been raised regarding the nature and/or identity of 
these cells. A 2009 study demonstrated that the RGC-5 cell line contained mouse, rather 
than rat, biomarkers (203). As recent as 2013, it was (235)demonstrated that RGC-5 cells 
were 661W cells, a mouse SV-40 T antigen-transformed photoreceptor cell line, rather 
than rat RGCs. There have been more than 230 publications that have used the RGC-5 
line to test various glaucoma-related hypotheses (237). Unfortunately, the outcomes of 
those investigations are very likely null and void. The lack of an authenticated RGC line 
represents a large unmet need for the vision research community at large. The 
heterogeneity of the cells in retina contributes to lack of reproducibility to isolate 
homogeneous RGCs. Therefore, to investigate RGCs cellular mechanisms, it is critical to 
develop such methodology. Commercially available kits for RGC isolation are exclusive 
for rats and for mice the protocols are based on magnetic separation and immunopanning. 
Both approaches require lengthy isolations and their yields vary. FACS is a powerful 
technique for analysis of cells in suspension allowing separation of cells based on 
parameters such as size and granularity, providing a quantitative and qualitative analysis 
with high sensitivity. The purification system using flow cytometry has not been 
standardized for the isolation of and standardization of primary murine RGCs from 
dissociated retinae. We can use this powerful technologyFACSas the first step of 
generating a stable, immortalized, homogeneous murine RGC population from murine 
retinae. 
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 Classically, IHC analyses of cross sections of ganglion cell layer flat mounts are 
used for the detection of surface and intracellular markers associated with RGC (207, 
208, 238, 239). Despite its extensive use there are a series of limitations such as fading 
and photobleaching of fluorescence, limited sensitivity and the presence of false-negative 
or false-positive results. The tissue structure may or may not allow appropriate exposure 
for the immune binding of proteins. Rather than the use of IHC for protein detection 
exclusively, the use of flow cytometry as a complement technique will provide a major 
sensitivity and a faster and more objective way to acquire and record data. 
 
 Enhancing RGC viability (neuroprotection) or RGC function (neuroenhancement) 
remains a major goal of basic and translational research. In future, such cell lines or 
isolate cells can be used to define the molecular biology of the process of ganglion cell 
death, by manipulating such biochemical events that occur in a dying ganglion cell to 
increase the chance of cell survival. Elucidation of cell death and neuro-protective 
pathways would lead to generation of novel therapeutic targets to prevent glaucoma 
progression. Other possibilities include, molecular profiling to identify and characterize 
the RGC subtypes which are the first targets of the disease—the cells most susceptible to 
the disease—and help devise new prevention and therapy. RGC-based screening 
technologies can be developed to enabled drug discovery scientists to develop models of 
interconnected cellular pathways, extract important information for specific disease 
models, and build companion diagnostic programs around relevant cellular biomarkers 
for therapeutics. The benefits from this work will pave the way for studying mechanisms 
of RGC neuroprotection and death in glaucoma and in future targeted neuroprotective 
strategies can be developed to treat glaucoma. 
 
 Our Aim 3 studies are innovative for the following reasons: 
1. We provide the first standardized method for the enrichment of adult murine 
primary RGC by FACS. 
2. LiveThy1+CD48neg phenotype is not the phenotype of a homogenous/pure RGC 
population. The stringency of the additional positive markers: Thy1.2 and 
negative cell surface: CD15, CD57, CD48 selection markers increased the 
homogeneity of the resultant RGC population. 
3. Our two step validation strategy included the use of qPCR and flow cytometry. 
The innovation is based on (1) pre-amplification od cDNA; (2) the combination of 
amplicons; (3) intracellular protein examination by flow cytometry. Our cutting 
edge gene transcriptional assays based on characterized the homogeneous 
population of the isolated cells and our flow cytometry strategy affirmed the 
purity of the isolated cells. 
4. Our sorting method enriches for a homogeneous population of RGCs. 
5. We provide the scientific community with a novel and fully validated 
methodology to isolate murine RGCs that can be used to dissect molecular 
mechanisms of cell damage/death in glaucoma as well as evaluate potential 
treatments for glaucoma. 
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Glaucomics—Future of Glaucoma Research 
 
 Visual disorders like glaucoma massively impact health, both in developed and 
developing countries. Visual disorders represent one of the largest health care 
expenditures in the United States, costing approximately $139 billion per year (240). A 
complex disease such as glaucoma is best conceptualized as a syndrome displaying a 
presumably common clinical end-point, but with heterogeneous molecular underpinnings 
and host–environment interactions. Despite advances in our understanding of the 
pathophysiology of glaucoma, the diagnostic criteria and associated endophenotypes are 
still evolving. Ophthalmology in the 21st century needs a fresh new look at the ways in 
which novel diagnostics are developed so as to catalyze true innovations for personalized 
healthcare. This thesis is an introduction of omics science and systems diagnostics to 
ophthalmology, a field that can benefit enormously from personalized medicine, and 
which has sadly lagged behind in systems diagnostics compared to fields such as 
oncology. Glaucomics offers tremendous opportunities to integrate glaucoma research 
and clinical practice with omics science, systems diagnostics, and personalized visual 
health. Glaucomics can be defined as “The integrated use of multi-omics and systems 
science approaches towards rational discovery, development, and tandem applications of 
diagnostics and therapeutics, for glaucoma specifically, and for personalized visual 
health” (241). Access to high-throughput technologies has enabled scientists and 
clinicians to examine genomes, transcriptomes, proteomes, metabolomes, and other 
omics information. By combining mouse and human omics data we can identify novel 
biomarkers and systems diagnostics for glaucoma. By isolating different retinal cell types 
contributing to glaucoma we can perform high throughput drug screening and high 
content data analysis to better understand cellular function (Figure 5-1). My dissertation 
is a step towards development of “Glaucomics” as a bridge between high throughput 
technology and visual health. Philosophers defined the eye as a window to the soul long 
before. Now as scientists we need address this cliché to determine its scientific basis and 
clinical relevance. 
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Figure 5-1. Glaucomics 
The integrated use of multi-omics and systems science approaches towards rational 
discovery, development, and tandem applications of diagnostics and therapeutics, for 
glaucoma specifically, and for personalized visual health. 
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APPENDIX A. SUPPLEMENTAL DATA FOR CHAPTER 2 
 
 
Table A-1. IOP values of BXD strains at 9.1-13 months age 
 
 
BXD 
Strains 
Average 
Female 
IOP 
Average 
Male 
IOP 
Overall 
IOP 
SE 
 
B6D2F1 18.25 17.00 17.63 0.38 
C57BL/6J 15.00 15.42 15.23 0.78 
DBA/2J 16.77 17.00 16.84 0.70 
BXD1 18.20 X 18.20 1.08 
BXD2 11.33 X 11.33 0.83 
BXD5 12.17 14.17 13.17 1.98 
BXD6 12.50 X 12.50 X 
BXD8 17.00 17.00 17.00 2.11 
BXD9 11.75 16.75 14.25 1.61 
BXD11 14.83 14.60 14.75 0.94 
BXD12 13.25 15.50 14.38 1.48 
BXD13 13.50 13.25 13.38 0.38 
BXD14 18.75 20.00 19.38 0.43 
BXD15 15.67 17.00 16.33 0.54 
BXD16 15.88 18.50 16.75 0.87 
BXD18 19.25 17.00 18.13 0.83 
BXD19 13.08 15.25 14.17 0.86 
BXD20 10.67 11.33 11.00 1.08 
BXD24 18.00 16.00 17.00 1.00 
BXD27 19.64 16.60 18.38 1.13 
BXD29 13.50 15.83 14.67 1.11 
BXD31 14.33 X 12.63 1.73 
BXD32 13.33 14.75 13.90 0.70 
BXD33 19.00 17.00 18.00 0.56 
BXD34 18.57 19.63 18.95 0.79 
BXD36 14.88 14.75 14.83 0.46 
BXD38 9.25 10.25 9.58 0.93 
BXD39 11.50 14.50 13.21 1.14 
BXD40 14.50 12.25 13.75 0.64 
BXD42 9.50 12.88 11.75 0.88 
BXD43 17.63 18.13 17.88 0.47 
BXD45 17.25 15.00 16.50 1.52 
BXD48 9.25 9.33 11.90 0.95 
BXD50 12.33 12.75 12.50 2.13 
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Table A-1. (continued) 
 
 
BXD 
Strains 
Average  
Female IOP 
Average 
Male 
IOP Overall IOP 
SE 
 
BXD51 18.50 17.40 17.89 1.50 
BXD55 14.50 15.17 15.00 0.60 
BXD56 18.31 20.00 18.88 1.20 
BXD60 14.38 14.50 14.45 0.59 
BXD61 17.68 19.80 18.24 1.66 
BXD62 12.10 17.75 14.61 1.93 
BXD63 X 17.33 17.33 0.60 
BXD65 13.88 14.33 13.45 0.88 
BXD66 15.33 20.88 18.50 1.47 
BXD67 16.50 18.50 17.50 0.71 
BXD68 18.63 13.25 16.83 1.90 
BXD69 16.77 18.50 17.04 0.55 
BXD70 17.63 14.13 16.46 0.96 
BXD71 11.50 13.83 12.50 2.07 
BXD73 15.83 18.29 17.94 0.90 
BXD75 15.50 14.20 14.85 0.67 
BXD77 18.00 17.50 17.64 1.46 
BXD83 13.50 16.75 16.21 0.75 
BXD84 14.50 12.63 13.75 0.74 
BXD85 16.43 15.71 16.07 1.14 
BXD86 16.67 X 16.67 1.28 
BXD87 18.50 15.30 16.50 0.89 
BXD89 14.15 16.50 14.54 0.65 
BXD90 15.83 14.50 15.30 1.57 
BXD92 14.17 13.83 14.00 1.62 
BXD95 18.13 17.38 17.75 1.39 
BXD98 18.80 18.50 18.69 0.72 
BXD99 18.50 18.00 18.25 0.32 
BXD100 16.33 17.50 16.55 0.65 
BXD101 13.25 X 13.25 0.83 
BXD102 14.67 16.50 15.28 1.12 
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Table A-2. Cacna2d1 expression in BXD strains whole eye 
 
BXD 
Strains 
Cacna2d1 
Expression 
SE 
B6D2F1 9.049 0.04 
D2B6F1 8.874 0.114 
C57BL/6J 9.498 0.071 
DBA/2J 7.543 0.148 
BXD1 7.927 0.355 
BXD2 7.813 0.338 
BXD5 7.646 0.102 
BXD6 7.759 0.058 
BXD8 8.883 0.15 
BXD9 7.502 0.602 
BXD11 7.314 0.42 
BXD12 7.833 0.117 
BXD13 8.847 0.4 
BXD14 8.897 0.625 
BXD15 8.827 0.397 
BXD16 7.517 0.017 
BXD18 9.241 0.353 
BXD19 7.749 0.352 
BXD20 7.674 0.241 
BXD21 8.793 0.02 
BXD22 9.086 0.378 
BXD23 8.852 0.558 
BXD24 9.148 0.118 
BXD25 8.884 0.227 
BXD27 7.531 0.13 
BXD28 8.819 0.008 
BXD29 7.478 x 
BXD31 7.685 0.384 
BXD32 8.097 0.449 
BXD33 8.472 0.743 
BXD34 9.105 0.405 
BXD36 7.85 0.184 
BXD38 7.408 0.275 
BXD39 9.111 0.653 
BXD40 7.836 0.313 
BXD42 7.668 0.259 
BXD43 7.69 0.334 
BXD44 9.096 0.376 
BXD45 7.705 0.102 
BXD48 7.516 0.488 
BXD48a (BXD96) 9.708 0.328 
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Table A-2. (continued) 
 
BXD Strain Cacna2d1 
Expression 
SE 
BXD50 9.399 0.11 
BXD51 8.319 0.429 
BXD55 9.159 0.439 
BXD56 9.31 0.067 
BXD60 7.585 0.158 
BXD61 9.035 0.14 
BXD62 7.754 0.048 
BXD63 7.885 0.127 
BXD64 7.812 0.026 
BXD65 9.086 0.029 
BXD65a (BXD97) 8.771 0.207 
BXD65b (BXD92) 7.708 0.129 
BXD66 8.727 0.359 
BXD67 9.088 0.248 
BXD68 8.456 0.634 
BXD69 7.846 x 
BXD70 7.552 0.3 
BXD71 6.91 0.239 
BXD73 9.506 0.058 
BXD73a (BXD80) 9.221 0.14 
BXD75 7.627 0.312 
BXD77 8.902 0.446 
BXD83 9.541 0.081 
BXD84 7.828 0.031 
BXD85 7.634 0.457 
BXD86 8.718 0.912 
BXD87 9.207 0.078 
BXD89 7.535 0.624 
BXD90 8.091 0.297 
BXD98 7.854 0.59 
BXD99 8.864 0.24 
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APPENDIX B. SUPPLEMENTAL DATA FOR CHAPTER 3 
 
 
Table B-1. Sncg expression in retina of BXD strains 
 
BXD Strain Sncg 
Expression 
SE 
B6D2F1 14.175 0.106 
D2B6F1 13.958 0.235 
C57BL/6J 13.747 0.147 
DBA/2J 14.267 0.095 
BXD1 13.772 0.071 
BXD2 13.995 0.188 
BXD5 14.15 0.127 
BXD6 13.513 0.359 
BXD8 13.669 0.252 
BXD9 13.716 0.066 
BXD11 14.413 0.085 
BXD12 13.761 0.087 
BXD13 12.68 0.15 
BXD14 13.71 0.135 
BXD15 12.652 0.035 
BXD16 13.205 0.315 
BXD18 12.84 0.124 
BXD19 13.68 0.3 
BXD20 13.744 0.107 
BXD21 13.488 0.211 
BXD22 14.169 0.09 
BXD24a 14.274 0.139 
BXD27 13.907 0.117 
BXD28 13.681 0.131 
BXD29 13.781 0.191 
BXD31 13.065 0.147 
BXD33 13.133 0.058 
BXD34 13.585 0.161 
BXD36 13.753 0.126 
BXD38 13.379 0.139 
BXD39 14.385 0.191 
BXD40 13.284 0.159 
BXD42 13.837 0.128 
BXD43 13.761 0.267 
BXD44 14.406 0.17 
BXD45 13.782 0.105 
BXD48 14.378 0.08 
BXD48a (BXD96) 14.363 0.08 
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Table B-1. (continued) 
 
BXD Strain Sncg 
Expression 
SE 
BXD50 14.031 0.176 
BXD51 13.875 0.151 
BXD53 13.847 0.089 
BXD55 13.799 0.293 
BXD56 13.076 0.192 
BXD60 13.698 0.208 
BXD61 14.469 0.157 
BXD62 13.859 0.204 
BXD63 13.717 0.173 
BXD65 13.832 0.046 
BXD65a (BXD97) 14.066 0.211 
BXD65b (BXD92) 13.901 x 
BXD66 13.473 0.244 
BXD67 14.07 0.227 
BXD68 13.716 0.199 
BXD69 13.685 0.205 
BXD71 14.327 0.472 
BXD73 13.283 0.264 
BXD73a (BXD80) 13.616 0.165 
BXD73b (BXD103) 13.552 0.14 
BXD74 13.843 0.192 
BXD75 13.957 0.278 
BXD77 14.361 0.147 
BXD81 14.184 0.277 
BXD84 14.197 0.217 
BXD85 13.768 0.187 
BXD86 13.915 0.226 
BXD87 13.557 0.098 
BXD90 13.706 0.127 
BXD95 13.7 0.244 
BXD98 14.315 0.148 
BXD99 14.356 0.111 
BXD100 13.78 0.324 
BXD101 14.012 0.152 
BXD102 14.074 0.227 
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Table B-2. Pfdn2 expression in BXD strains retina 
 
BXD Strain Pfdn2 
Expression 
SE 
B6D2F1 13.707 0.23 
D2B6F1 13.696 0.263 
C57BL/6J 13.628 0.215 
DBA/2J 13.843 0.235 
BXD1 13.674 0.137 
BXD2 13.682 0.25 
BXD5 13.265 0.309 
BXD6 13.555 0.141 
BXD8 13.206 0.285 
BXD9 13.405 0.081 
BXD11 13.906 0.088 
BXD12 13.561 0.109 
BXD13 12.492 0.104 
BXD14 13.719 0.199 
BXD15 12.786 0.135 
BXD16 13.714 0.408 
BXD18 12.492 0.085 
BXD19 13.267 0.15 
BXD20 14.136 0.108 
BXD21 13.767 0.219 
BXD22 13.309 0.267 
BXD24a 13.952 0.277 
BXD27 14.017 0.199 
BXD28 13.353 0.223 
BXD29 13.626 0.135 
BXD31 13.001 0.094 
BXD33 13.535 0.339 
BXD34 13.238 0.298 
BXD36 13.87 0.229 
BXD38 13.465 0.199 
BXD39 14.415 0.196 
BXD40 13.064 0.205 
BXD42 13.65 0.322 
BXD43 13.57 0.497 
BXD44 14.028 0.411 
BXD45 13.774 0.186 
BXD48 13.53 0.108 
BXD48a (BXD96) 13.553 0.134 
BXD50 13.625 0.225 
BXD51 14.319 0.193 
BXD53 13.45 0.216 
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Table B-2. (continued) 
 
BXD Strain Pfdn2 
Expression 
SE 
BXD55 13.366 0.265 
BXD56 13.302 0.194 
BXD60 13.047 0.305 
BXD61 14.066 0.246 
BXD62 13.371 0.314 
BXD63 13.555 0.187 
BXD65 13.473 0.254 
BXD65a (BXD97) 13.891 0.177 
BXD65b (BXD92) 13.377 x 
BXD66 13.38 0.402 
BXD67 13.701 0.208 
BXD68 13.408 0.172 
BXD69 13.586 0.358 
BXD71 13.792 0.477 
BXD73 13.085 0.314 
BXD73a (BXD80) 13.974 0.209 
BXD73b (BXD103) 13.268 0.1 
BXD74 13.052 0.041 
BXD75 13.484 0.224 
BXD77 13.966 0.165 
BXD81 13.179 0.226 
BXD84 13.239 0.122 
BXD85 13.546 0.245 
BXD86 13.821 0.222 
BXD87 13.627 0.211 
BXD90 13.458 0.353 
BXD95 13.546 0.21 
BXD98 13.413 0.196 
BXD99 13.897 0.293 
BXD100 13.416 0.199 
BXD101 13.703 0.192 
BXD102 13.382 0.238 
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Table B-3. Gene ontology of Cytochrome-c oxidase activity 
 
Database: molecular function    Name: Cytochrome-c oxidase activity    ID:GO:0004129 
C=16; O=2; E=0.12; R=17.06; rawP=0.0060; adjP=0.0590 
Index User ID Gene  
Symbol 
Gene Names Entrez  
Gene 
Ensembl 
1 ILMN_2657141 Surf1 Surfeit gene 1 20930 ENSMUSG00000015790 
      
2 ILMN_1254971 Cox6b1 Cytochrome c oxidase, subunit VIb polypeptide 110323 ENSMUSG00000036751 
 
 
 
 
Table B-4. Gene ontology for NADH dehydrogenase activity 
 
Database: molecular function   Name: NADH dehydrogenase activity    ID:GO:0003954 
C=18; O=2; E=0.13; R=15.17; rawP=0.0075; adjP=0.0590 
Index User ID Gene  
Symbol 
Gene Names Entrez  
Gene 
Ensembl 
1 ILMN_1220362 Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 12 
66414 ENSMUSG00000020022 
      
2 ILMN_2985053 Ndufv2 NADH dehydrogenase (ubiquinone) 
flavoprotein 2 
72900 ENSMUSG00000024099 
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Table B-5. Gene ontology for oxidoreductase activity 
 
Database: molecular function    Name: oxidoreductase activity    ID:GO:0016491 
C=663; O=11; E=4.86; R=2.26; rawP=0.0095; adjP=0.0590 
Index User ID Gene  
Symbol 
Gene Names Entrez  
Gene 
Ensembl 
1 ILMN_2752552 Sod1 Superoxide dismutase 1, soluble 20655 ENSMUSG00000022982 
      
2 ILMN_2610531 Spr Sepiapterin reductase 20751 ENSMUSG00000033735 
      
3 ILMN_1220362 Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 12 
66414 ENSMUSG00000020022 
      
4 ILMN_2657141 Surf1 Surfeit gene 1 20930 ENSMUSG00000015790 
      
5 ILMN_1258815 Jmjd1c Jumonji domain containing 1C 108829 ENSMUSG00000037876 
      
6 ILMN_2985053 Ndufv2 NADH dehydrogenase (ubiquinone) flavoprotein 2 72900 ENSMUSG00000024099 
      
7 ILMN_2512849 Uqcrh Ubiquinol-cytochrome c reductase hinge protein 66576 ENSMUSG00000063882 
      
8 ILMN_1220100 Ywhae Tyrosine 3-monooxygenase/ 
Tryptophan 5-monooxygenase activation protein, 
epsilon polypeptide 
22627 ENSMUSG00000020849 
      
9 ILMN_2594149 Sdhc Succinate dehydrogenase complex, subunit C, 
integral membrane  
protein 
66052 ENSMUSG00000058076 
      
10 ILMN_1254971 Cox6b1 Cytochrome c oxidase, subunit VIb polypeptide 1 110323 ENSMUSG00000036751 
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Table B-6. Gene ontology for hydrogen ion transmembrane transporter activity 
 
Database: molecular function    Name: hydrogen ion transmembrane transporter activity    ID:GO:0015078 
C=71; O=4; E=0.52; R=7.69; rawP=0.0018; adjP=0.0590 
Index User ID Gene  
Symbol 
Gene Names Entrez  
Gene 
Ensembl 
1 ILMN_2657141 Surf1 Surfeit gene 1 20930 ENSMUSG00000015790 
      
2 ILMN_1254971 Cox6b1 Cytochrome c oxidase, subunit VIb polypeptide 1 110323 ENSMUSG00000036751 
      
3 ILMN_1249783 Atp5c1 ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1 
11949 ENSMUSG00000025781 
      
4 ILMN_2512849 Uqcrh Ubiquinol-cytochrome c reductase hinge protein 66576 ENSMUSG00000063882 
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Table B-7. Gene ontology for structural constituent of ribosome 
 
Database: molecular function    Name: structural constituent of ribosome    ID:GO:0003735 
C=81; O=4; E=0.59; R=6.74; rawP=0.0030; adjP=0.0590 
Index User ID Gene  
Symbol 
Gene Names Entrez 
Gene 
Ensembl 
1 ILMN_1229110 Mrpl33 Mitochondrial ribosomal  
protein L33 
66845 ENSMUSG00000029142 
      
2 ILMN_2646163 Rpl7 Ribosomal protein L7 19989 ENSMUSG00000043716 
      
3 ILMN_2883147 Mrpl12 Mitochondrial ribosomal  
protein L12 
56282 ENSMUSG00000039640 
      
4 ILMN_1236904 Mrpl23 Mitochondrial ribosomal  
protein L23 
19935 ENSMUSG00000037772 
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APPENDIX C. SUPPLEMENTAL DATA FOR CHAPTER 4 
 
 
Table C-1. List of primers used for gene expression analysis as a component of 
the validation of RGC enrichment protocol  
 
Gene symbol Taqman® Gene Expression assays 
(Primers) 
 
Abca8a Mm00462440_m1 
Aldh1al Mm00657317_m1 
Aqp4 Mm00802131_m1 
Calb2 Mm00801461_m1 
Cd68 Mm03047340_m1 
Gad2 Mm00484623_m1 
Hprt Mm01545399_m1 
Lhx1 Mm01297482_m1 
Lim2 Mm00624623_m1 
Nrl Mm00476550_m1 
Ntrk1 Mm01219406_m1 
Pcp4 Mm00500973_m1 
Pov4f1 Mm02343791_m1 
Prdx6 Mm00725435_s1 
Prkca Mm00440858_m1 
Prox1 Mm00435969_m1 
Pvalb Mm00443100_m1 
Rbpms Mm02343791_m1 
Rom1 Mm00436364_g1 
Rpe65 Mm00504133_m1 
Slc1a3 Mm00600697_m1 
Slc6a9 Mm00433662_m1 
Sncg Mm00488345_m1 
Tubb3 Mm00727586_s1 
Vim Mm01333430_m1 
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